BE IN A POSITION TO SUCCEED.

DUOTRAV™ Solution, combining two powerful agents into a single bottle, decreases IOP by up to 38% (12mmHg) from baseline.¹ DUOTRAV™ Solution's convenient once-a-day dosing, either morning or evening, enhances patient compliance. BE IN A POSITION TO SUCCEED in the management of glaucoma.

Dear colleagues and friends,

It’s a great pleasure to invite you to our annual meeting.

EVER continues to improve and grow. This year marks EVERs 10th year and is characterised by the most comprehensive scientific program ever offered in our history. I am pleased that we have been able to outline an excellent scientific program with almost 40 Special Interest Symposia covering a wide range of up-to-date topics. In addition, six Plenary Lectures will be delivered by international guests of EVER focusing on important progress made in basic and clinical research. Some of you may have made already plans to arrive on Wednesday to attend one of our six courses. You may notice that for the first time we have been grading them from beginner through advanced level that allows you to make an even better, individual choice.

It is becoming a tradition for EVER to host other international organisations and to organise combined sessions with ARVO, EVI, ISCEV, FRO and OOG. This not only strengthen our already excellent scientific program but also emphasises the international reputation that EVER has achieved. EVER is happy to consider similar collaboration with other societies.

Our new venue is Portoroz in Slovenia situated at the Adriatic coast. The congress center and facilities there will guarantee optimal conditions for our extended program. At the same time Portoroz provides us the relaxed atmosphere that will stimulate exchange and communication with friends and colleagues. EVER will provide a social program, including a welcome reception, cultural events and a dinner at a historical location. I am sure that these perspectives will make the EVER meeting this year a great scientific and social event!

Looking forward to welcome you in Portoroz,

Yours Sincerely,

Prof. Dr. Uwe Pleyer, FEBO
About EVER
EVER is a non-profit organisation. The aims of the Association are to encourage research and the dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange of information.

EVER is currently the leading ophthalmological research association in Europe which covers all areas of ophthalmology and visual sciences.

Membership
Membership is open to individuals of any nationality, engaging in or with an interest in ophthalmic and vision research, who meet the requirements established by the EVER Board. To become a member, a candidate should apply on the member’s module, on www.ever.be and fill in the name of an EVER member who will endorse their application. If candidates do not know a member who can endorse their application, they should write to the EVER office, who will take appropriate action. The candidate becomes a member upon recommendation by the EVER board and upon payment of the dues.

As EVER member your benefits are:
- reduced fee for the annual meeting
- possibility of organizing Special Interest Symposia (SIS) during the annual meeting
- voting rights for the election of the Board Members
- free electronic subscription to Acta Ophthalmologica Scandinavica, the EVER journal
- travel grants for best paper in each section

Elections
This year, the term of Secretary General is coming to an end. Elections for a new Secretary General are open to all full members. The list of candidates is on the member’s web page.

Also new representatives of the scientific sections Cornea/Ocular Surface and Glaucoma will be elected through electronic voting. The result of the elections will be announced at the General Assembly on Saturday, October 6, 2007.

The scientific sections will hold their Business Meetings on Friday, October 5, 2007 from 19:00 till 20:00. The agenda is available on page 42.

The sections on Lens and Cataract and on Retina/Vitreous will nominate candidates for the succession of their representatives in the Board of EVER for elections in 2008.

The statutes and by-laws are available on the website: www.ever.be » about » statutes
Location
EVER 2007 will be held at the Bernardin Convention Center in Portorož, Slovenia (visit the website on www.h-bernardin.si).

The scientific programme starts on Wednesday, October 3 at 14:00 and concludes on Saturday, October 6 at 19:00.

Registration
Everyone attending the scientific sessions—whether or not an EVER member, invited speaker, accompanying person or presenter—must register and pay the registration fee.

The early registration deadline is September 1, 2007. At any time, you can register and pay your registration fee on-line at www.ever.be. On-site registration will be open from Wednesday on October 3, 12:00.

Please note that:

- being or becoming an EVER member – or having an abstract accepted – does not imply that you are registered
- if you register as a member-in-training, you need to prove your traineeship with a document signed by the Head of your Department
- registering as an accompanying person entitles you to attend the EVER social events, but not the scientific programme
- refunds – up to 75% of the registration fee – will be granted for any cancellation received in writing, prior to September 20, 2007. Refunds will not be granted for later cancellation or no-shows.

Registration fees (in EUR) after Sept. 1, 2007

<table>
<thead>
<tr>
<th>Category</th>
<th>Member</th>
<th>Non-member</th>
</tr>
</thead>
<tbody>
<tr>
<td>EVER member</td>
<td>350</td>
<td>570</td>
</tr>
<tr>
<td>SIS-invited speaker</td>
<td>350</td>
<td>570</td>
</tr>
<tr>
<td>Member-in-training</td>
<td>175</td>
<td>570</td>
</tr>
<tr>
<td>Non-member</td>
<td>140</td>
<td>460</td>
</tr>
<tr>
<td>Non-member-in-training</td>
<td>280</td>
<td>220</td>
</tr>
<tr>
<td>Course</td>
<td>50</td>
<td>30</td>
</tr>
<tr>
<td>Accompanying person</td>
<td>115</td>
<td>115</td>
</tr>
</tbody>
</table>

* Only for citizens of listed countries: Albania, Algeria, Armenia, Belarus, Bosnia and Herzegovina, Bulgaria, Congo, Croatia, Czech Republic, Egypt, Estonia, Georgia, Hungary, India, North Korea, Latvia, Libya, Lithuania, Macedonia, Moldova, Morocco, Poland, Romania, Russia, Serbia and Montenegro, Slovakia, Slovenia, Tunisia, Turkey, Ukraine
The list of countries will be updated annually and is based on the membership roster.

Website
The EVER website www.ever.be has a central role in the EVER organisation. At this website, you can

- obtain up-to-date information about the scientific programme and the EVER 2007 meeting and view the status (session, hour, place) of your presentation
- pay on-line and obtain an overview of past payments
- look for other EVER members
- access general information about EVER
- access Acta Ophthalmologica, the EVER journal
- go to useful links
- express your vote for officers
- print your CME certificate after the congress
**Travel**

Portoroz can be reached from Trieste airport and from Ljubljana airport.

A congress shuttle service is available. Please book in advance through [www.ever.be](http://www.ever.be) > housing and transfer.

- Congress Transfer Service* from Ljubljana and Trieste airport to Portoroz: on arrival dates October 2 and October 3.
- On departure dates October 6 and October 7.
- One-way shuttle bus transfer:
  - Ljubljana airport - Portoroz: 25 EUR per person,
  - Trieste airport - Portoroz: 20 EUR per person.
- Private transfer: individual service, private car or van transfer with English-speaking driver can be organised. Please contact the technical organiser for more details at housing@cd-cc.si.

* Arrivals: The congress transfer service reserves the right to combine transfers for participants of the EVER congress with a maximum waiting time of 1 hour.

Departures: Please reconfirm your departure transfer at least 48 hrs prior to your departure at the housing desk.

**Tourist information**

Slovenia is a country where the Alps meet the sea, a country of geographical diversity and natural beauty that you will be able to observe already on the way from Ljubljana airport to the town of Portoroz. Portoroz and Piran are two towns next to each other. The old tradition of Piran is matched with modern amenities in hotels that offer relaxing atmosphere and splendour.

The congress center is situated right in the middle of the two. The towns have many places offering pleasant atmosphere, with seafood restaurants and delicious wines.

**Weather**

October is an excellent time to visit Slovenia. It is the latter part of the warmest and driest time of the year.

**Liability**

The organisers cannot accept liability for personal accidents, loss of or damage to private property of participants and accompanying persons either during, or directly arising from the Meeting. Participants should make their own arrangements with respect to health and travel insurance.

**Social programme**

The social programme is open for all participants and registered accompanying persons:

- Wednesday 19:00, the EVER Welcome reception
- Saturday 20:00, the Congress dinner

**Coffee**

Coffee and soft drinks are provided throughout the meeting from 09:30 until 11:00 and from 15:30 until 17:30 and are included in the registration fee.

**Internet access**

Wi-Fi internet access will be provided in room Europa C.

**Scientific programme access**

You can visit [www.ever.be](http://www.ever.be) for the most up-to-date scientific programme.

The abstracts will be published on-line in a special issue of Acta Ophthalmologica Scandinavica.
**TFOS awards 2007**

We are pleased to announce that the following three researchers have received a travel award from the Tear Film and Ocular Surface Society for the three best abstracts submitted to EVER 2007 by young researchers in the cornea section:

- **Maria Fideliz DE LA PAZ, Barcelona, Spain**
  Wedge resection for high astigmatism in penetrating keratoplasty for keratoconus: refractive and histopathologic changes

- **Laurent BATAILLE, Alicante, Spain**
  Influence of platelets on the healing of dry eye of patients treated with topical eyes of autologous Platelet-Rich Plasma (PRP)

- **Pier Luigi DODI, Parma, Italy**
  NGF topical administration in dogs affected by spontaneous keratoconjunctivitis sicca

**Business meetings**

- European Vision Institute, EVI
  General Assembly, Friday, 16:00-18:00, in room Nautilus

- EVER business meetings of the scientific sections
  Friday, 19:00-20:00
  COS / ACB, in room Europa A
  RV / IM, in room Europa B
  G / MBGE, in room Emerald I
  LC / NSPH, in room Emerald II
  PBP / VEP, in room Mediterranea I
  PO, in room Adria

- European Board of Ophthalmology, EBO
  Saturday, 12:50-15:30, in room VIP

- Ophthalmic Oncology Group, OOG
  Saturday, 16:30-18:00, in room Adria
Photographs
It is strictly forbidden to take photographs or videos of the presentations in the lecture rooms.

Withdrawals
First authors unable to attend EVER for reasons beyond their control, may request permission of the Programme Secretary to have another author present the paper. Alternatively, they should send a written notice of withdrawal to the EVER Office before September 20, 2007.

No shows
Please note that any first author, whose paper or poster, once it has been accepted, is not presented without a valid excuse, will be prohibited from presenting papers at EVER for the next two years.

Guidelines for speakers: handling presentations at EVER 2007
EVER 2007 offers a high-performance network between all the different presentation rooms.

All presenters must read the following instructions:
The supported software for presentation is PowerPoint
Oral presentations in the free paper sessions are limited to eight minutes, followed by four minutes of discussion. The session chairman will strictly enforce this schedule.
Rapid fire presentations should last no longer than 3-4 minutes with a 2 further minutes for questions from the audience. Do not use more than 2-3 PowerPoint slides for this presentations.
In the Speaker’s room Mediterranea II, a technician helps the speaker to transfer his or her presentation into the central congress network. When the transfer is complete, the technician performs a quick run of the presentation so the speaker can check whether the presentation runs correctly and all parts of the presentation are copied.
Inside each presentation room, a technical assistant starts each presentation at the right time using one of the fixed computers connected to the central congress network.
We do not allow the use of personal laptops for presentations except in rare circumstances*. If you bring your laptop to the congress, the technician will copy the files on your hard disk of the laptop into the central congress network, so the laptop will no longer be needed. Of course, the easiest way is to bring your presentation on CD, DVD or memory stick. E-mailing or uploading of presentations will not be encouraged but can be used in special circumstances.

When a speaker wants to modify the presentation after it has been transferred to the central congress network, it can of course be updated to the new version upon request.
At the end of the congress, all presentations will be deleted so no copyright issues will arise.

Guidelines for posters
The poster exhibition takes place in Room Europa C. Posters must be brought to the congress by the presenting author and should not be mailed in advance. The required dimensions are 95 cm (width) by 180 cm (height). NOTE: Portrait shape.
Each poster is exhibited for one day only. You should install your poster in the morning before 9:00 and remove it the same day after 19:00. EVER is not responsible for any poster left behind at the end of the day.
You will find the number of your posterboard in one of the poster sessions of this programme book.
You should ensure that you are standing beside your poster during the poster session. On Thursday and Friday from 16:30 to 17:25, on Saturday from 15:35 to 16:25. During this time, moderators will be voting which poster should win the poster prize.
Some authors of posters, selected by the programme committee will be invited to give a brief rapid fire oral presentation.

Poster prizes
A poster prize of 100 EUR will be awarded for the best poster in each section. The winners will be chosen by the moderators and will be announced in the General Assembly meeting on Saturday, 6 October.

* In rare circumstances, the technician will allow the use of personal laptops. For example, when the presentation has been created with Corel, Apple Keynote or movie creating software.
**EVER travel grants**

We are pleased to announce that the following 11 members have received a travel grant of 400 EUR each from the EVER Sections:

- Anatomy/Cell Biology:
  Kati-Sisko VELLONEN, Helsinki, Finland
- Cornea / Ocular Surface:
  Gilles THURET, Saint-Etienne, France
- Glaucoma:
  Raquel FERNANDEZ DURANGO, Madrid, Spain
- Immunology/Microbiology:
  Valerie TOUITOU, Paris, France
- Lens and Cataract:
  Sally CHE, Auckland, New Zealand
- Molecular Biology/Genetics/Epidemiology:
  Oliver PUK, Neuherberg, Germany
- Neuro-ophthalmology/Strabismology/Paediatric Ophthalmology/History:
  Lajos Rudolf KOZAK, Budapest, Hungary
- Pathology/Oncology:
  Bruno FERNANDES, Montreal, Canada
- Physiology/Biochemistry/Pharmacology:
  Simon BACKHOUSE, Auckland, New Zealand
- Retina/Vitreous:
  Irmela MANTEL, Lausanne, Switzerland
- Vision Sciences/Electrophysiol./Physiol. Optic:
  Marika WAHLBERG, Hägersten, Sweden
10th anniversary congress

Wednesday 3 October
### Europa A

**Course 1: Amniotic membrane in ophthalmology: Applications and limitations**

Haminder S DUA, Jean-Jacques GICQUEL

14:00 – 16:45

The amniotic membrane has been prolifically used in ophthalmology for almost two decades. With cumulative clinical experience and continued scientific analysis of the membrane clear benefits and limitations of the membrane are now established. The major advantage is that in some clinical indications it offers a management option where none existed and the clear disadvantage is that the membrane is far from standardised resulting in variable, often unsuccessful outcomes. This is borne out by extensive biochemical and proteomic studies. This course will aim to start from basics and cover history, clinical indications, applications and limitations of the membrane with video illustrations. Results of scientific studies and their clinical implications will be discussed.

Current attempts to standardise the membrane or generate a consistent synthetic membrane will be introduced.

The attendee should be able to leave better informed and with a better understanding of the scientific basis of the proposed mechanisms of action; clinical including surgical tips on the use of the membrane; what to expect in different indications and how to evaluate outcomes.

All speakers have extensive clinical and research experience on the handling and use of the membrane.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>1311 Amniotic Membrane Transplantation (AMT): Historical overview</td>
</tr>
<tr>
<td></td>
<td>DUA HS—Nottingham</td>
</tr>
<tr>
<td>14:05</td>
<td>1312 Clinical applications and benefits of amniotic membrane</td>
</tr>
<tr>
<td></td>
<td>MAHARAJAN S—Nottingham</td>
</tr>
<tr>
<td>14:20</td>
<td>1313 Amniotic Membrane Transplant (AMT): Evaluation of Outcomes</td>
</tr>
<tr>
<td></td>
<td>DUA HS, HOPKINS A—Nottingham</td>
</tr>
<tr>
<td>14:35</td>
<td>1314 Limitations of the amniotic membrane</td>
</tr>
<tr>
<td></td>
<td>HOPKINS A—Nottingham</td>
</tr>
<tr>
<td>14:50</td>
<td>Surgical Videos: tips and techniques</td>
</tr>
<tr>
<td>15:15</td>
<td>1315 Future Directions: Standardised membranes and synthetic membranes</td>
</tr>
<tr>
<td></td>
<td>GICQUEL J—Potiers</td>
</tr>
</tbody>
</table>

### Europa B

**Course 2: Corneal infectious diseases**

Jean-Jacques GICQUEL, Tristan BOURCIER

14:00 – 16:45

Acanthamoeba keratitis, infectious crystalline keratopathy, fungal keratitis and atypical mycobacterial keratitis have emerged as important types of infectious keratitis. These corneal infections have often been associated with contact lens wear, with corneal surgery such as radial keratotomy or penetrating keratoplasty and with the uncontrolled use of topical steroids. The clinical setting of each of these infections is important in alerting the clinician to the possible diagnosis. There have been improvements in rapid diagnostic techniques for such infections in the last years. Treatment has also improved, but remains a difficult problem, especially for Acanthamoeba. In this course, we’ll give you an overview of recent developments in the clinical and histopathologic methods for diagnosis and treatment options of these corneal infections.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>1321 Bacterial keratitis</td>
</tr>
<tr>
<td></td>
<td>BOURCIER T—Strasbourg</td>
</tr>
<tr>
<td>14:30</td>
<td>1322 Parasitic infection</td>
</tr>
<tr>
<td></td>
<td>KOUKIAN L—Lyons</td>
</tr>
<tr>
<td>15:00</td>
<td>1323 Corneal fungal infections: practical diagnosis and treatment</td>
</tr>
<tr>
<td></td>
<td>GICQUEL J—Potiers</td>
</tr>
</tbody>
</table>

### Emerald I

**Course 3: Pediatric ophthalmology examination**

Lene MARTIN, Pinar AYDIN

14:00 – 16:45

Ophthalmological examination of pediatric patients requires special techniques and skills. This course is aiming to teach practical information and skills in:
1. Examining children with multiple handicaps
2. Measuring and evaluating binocular vision
3. Measuring vision in children
4. Assessing eye movements

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>1331 Measuring vision in children</td>
</tr>
<tr>
<td></td>
<td>MARTIN L—Stockholm</td>
</tr>
<tr>
<td>14:25</td>
<td>1332 Examining children with multiple handicaps</td>
</tr>
<tr>
<td></td>
<td>ARING E—Goteborg</td>
</tr>
<tr>
<td>14:50</td>
<td>1333 Measuring and evaluating binocular vision</td>
</tr>
<tr>
<td></td>
<td>BRAUTAGET R—Stockholm</td>
</tr>
<tr>
<td>15:15</td>
<td>1334 Assessing eye movements</td>
</tr>
<tr>
<td></td>
<td>BERK T—Izmir</td>
</tr>
</tbody>
</table>
Emerald II  **Course 4: Introduction in statistics**  14:00 – 16:45  
Course  Daniel MOJON, Stefania MOJON - AZZI  

During this course the basic principles of statistics relevant to biomedical research will be transmitted in an interactive way. The following topics will be covered: design of experiments, sampling, scales of measurement, descriptive statistics, parametric and non-parametric tests, one-sided and two-sided tests, paired and unpaired tests, regression and correlation, confidence intervals, multiple comparisons, power of tests, and bias.

Mediterranea I  **Course 5: Diagnosis and management of endophthalmitis**  14:00 – 16:45  
Course  Marc D DE SMET, Laurent KODJIKIAN  

The endophthalmitis course is meant to cover current concepts on the epidemiology, pathophysiology and management of common causes of endophthalmitis. The participant will be able to place the Endophthalmitis Vitrectomy Study in a proper context 15 years after its completion. He/she should be capable of recognizing tell-tale signs of endophthalmitis and choose an appropriate course of action, including the choice, mode of delivery, and frequency of administration of antibiotics. Also discussed will be the role and need for PCR and culture in establishing a diagnosis, and the timing and need for surgical intervention / debridement of the intraocular space. Plenty of time will be devoted to discussion of cases and therapeutic approaches with a faculty composed of leading European experts.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>1351 Endophthalmitis epidemiology - types of bacteria involved, their frequency, settings where it occurs (lens types etc) KODJIKIAN L–Lyon</td>
</tr>
<tr>
<td>14:15</td>
<td>1352 Preventative measures - wound design in cataract surgery, wound integrity and the use of intracameral antibiotics MONTAN P–Stockholm</td>
</tr>
<tr>
<td>14:30</td>
<td>1353 Diagnosis - when to suspect, what to do, how and when, what to expect from the microbiology lab. The role of PCR in the diagnosis BODAGHI B–Pars</td>
</tr>
<tr>
<td>14:45</td>
<td>1354 Choice of antibiotics and how long to treat COCHEREAU IC–Angers</td>
</tr>
<tr>
<td>15:00</td>
<td>1355 Surgical management of endophthalmitis standard post-op cases EVS or post EVS DE SMET M–Antwerp</td>
</tr>
<tr>
<td>15:15</td>
<td>1356 Surgical management of specific cases post traumatic / bleb / intravitreal injection ABU EL ASRAR A–Riyadh</td>
</tr>
</tbody>
</table>

Adria  **Course 6: Ophthalmologic pathology: Basics, updates and new insights**  14:00 – 16:45  
Course  Sarah COUPLAND, Karin LOEFFLER  

The aim of this course is to provide a basic overview of ophthalmic pathology, its continuing role in modern ophthalmology, and to provide practical guidelines for the evaluation of ocular specimens of varying types (e.g., diagnostic vitrectomies, conjunctival, orbital and choroidal biopsies, enucleated eyes as well as enucleated specimens). Furthermore, the course will cover newer technologies and methodologies in diagnostics, such as polymerase chain reaction (PCR), fluorescence in-situ hybridization (FISH) as well as gene expression profiling, and how these can be incorporated into the diagnostic panel in ophthalmic pathology. This course will be based on examples from real life and will be given from a practical rather than theoretical point of view. It is aimed at ophthalmologists with an interest in pathology, as well as at pathologists and basic researchers specializing in ocular pathology.

Daphnia  **Course 7: European Board of Ophthalmology (EBO) exam course**  14:00 – 16:45  
Course  Bahram BODAGHI, Marc D. DE SMET, Carl P. HERBORT, Piergiorgio NERI, Carlos E. PAVESIO, Uwe PLEYER  

Refreshment course on UVEITIS for the preparation of the EBO examination (www.ebo-online.org/ebod). The aim of this course is the review five major topics of intraocular inflammation and infections. A pre-test composed of multiple choice questions will evaluate the basic knowledge of the participants initially. The test will be followed by quiz and case presentations in different basic or more challenging situations. Important points will be discussed during each practical situation. The course will be interactive allowing general discussion and the participation of the audience. It will be basic and aimed at pathologies that are frequent. A post-test will be provided in order to evaluate the acquisition of knowledge.
Opening Ceremony

10th anniversary congress
Welcome by the President EVER 2007
Uwe PLEYER — President

On considerations of the corneal thickness
Niels EHlers, Aarhus - Denmark
Introduction by Anthony BRON

From Helmholtz to the scanning laser ophthalmoscope
150 years ophthalmoscopy
Jean-Jacques DE LAEY, Ghent - Belgium
Introduction of the series by Tero KIVELÄ

Can uveal melanoma be conquered?
Tero KIVELÄ, Helsinki - Finland
Introduction by Uwe PLEYER

Opening concert
Zoran Predin, acoustic guitar
Anja Bukovec, violin
Zoran Skinja, piano

EVER Welcome reception
On the St. Bernardin terrace
10th anniversary congress

Thursday
4 October
## THURSDAY

### FIRST MORNING SESSION

#### Europa A  
**Ocular zoonosis and uveitis**  
SIS
Lucent KODJIKIAN, Marc D DE SMET

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>2111</td>
<td>Lyme disease (Borreliosis)</td>
<td>BOURCIER T–Strasbourg</td>
</tr>
<tr>
<td>08:42</td>
<td>2112</td>
<td>Bartonellosis</td>
<td>GARWEG J–Bern</td>
</tr>
<tr>
<td>08:54</td>
<td>2113</td>
<td>Toxocariasis</td>
<td>HERBORT C–Lausanne</td>
</tr>
<tr>
<td>09:06</td>
<td>2114</td>
<td>Leptospirosis</td>
<td>LIESENFELD O–Berlin</td>
</tr>
<tr>
<td>09:18</td>
<td>2115</td>
<td>Brucellosis</td>
<td>DE SMET M–Antwerp</td>
</tr>
<tr>
<td>09:30</td>
<td>2116</td>
<td>Ocular toxoplasmosis</td>
<td>KODJIKIAN L–Lyons</td>
</tr>
<tr>
<td>09:42</td>
<td>2117</td>
<td>Prion disease</td>
<td>BODAGHI B–Paris</td>
</tr>
</tbody>
</table>

#### Europa B  
**Free Papers: Epidemiology and genetics**  
FP
Jeremy GUGGENHEIM, Teodosio LIBONDI

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>2121</td>
<td>Age-related cataracts in a German population-based study (KORA S4)</td>
<td>GRAW J, KLOPP N, ILLEG T, GIEGER C, WELZ G, LAHMAANN G, HOLLE R, WICHMANN HE–Neuenberg</td>
</tr>
<tr>
<td>08:42</td>
<td>2122</td>
<td>The ocular and systemic factors associated with diabetes mellitus in the Beijing eye study</td>
<td>LIBONDI T, XU L, XIE X, WANG Y, JONAS J–Naples, Beijing, Mannheim</td>
</tr>
<tr>
<td>08:54</td>
<td>2123</td>
<td>Genotype–phenotype correlation in AMD: The influence of complement factor H polymorphism</td>
<td>MAINTER I, DROZ I, AMBRESIN A, SCHORDERET D, MUNIER F–Lausanne, Sion</td>
</tr>
<tr>
<td>09:06</td>
<td>2124</td>
<td>Genetic markers for proliferative diabetic retinopathy in type 2 diabetes</td>
<td>GLOBOCNIK PETROVIC M, HAWUNA M, PETERLIN BORUT, PETROVIC D–Ljubljana</td>
</tr>
<tr>
<td>09:18</td>
<td>2125</td>
<td>Congenital aniridia</td>
<td>POPPER M, BAUSZ M, TURI E, SENIY K, KHEZY K, SUVEGES I–Budapest</td>
</tr>
<tr>
<td>09:30</td>
<td>2126</td>
<td>Clinical management of congenital achromatopsia</td>
<td>PINELL L, MAZZAROLO M, MAIMONE PE, SUPPIEJA, CALDIRONI P–Padua</td>
</tr>
<tr>
<td>09:36</td>
<td>2127</td>
<td>Family with Brittle Cornea Syndrome</td>
<td>TOSQUINDIS IH, MCKEAS D, AU L, AULTALLAH S, BLACK G, BONSHAK RE–Manchester</td>
</tr>
</tbody>
</table>

#### Emerald I  
**Adherence with medical therapy**  
SIS
Anastasios G.P. KONSTAS

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>2131</td>
<td>The problem of non-adherence with medical therapy</td>
<td>GEORGIOADOU I–Thessaloniki</td>
</tr>
<tr>
<td>08:45</td>
<td>2132</td>
<td>Adherence with antiglaucoma therapy</td>
<td>CARASSA AG–Milano</td>
</tr>
<tr>
<td>09:00</td>
<td>2133</td>
<td>Patient reported problems and adherence to glaucoma medications in the United States and India</td>
<td>SLEATH B–Chapel Hill (North Carolina)</td>
</tr>
<tr>
<td>09:15</td>
<td>2134</td>
<td>Fixed combinations and adherence</td>
<td>HOLLO G–Budapest</td>
</tr>
<tr>
<td>09:30</td>
<td>2135</td>
<td>Objective evaluation of adjunctive glaucoma therapy</td>
<td>ROBIN A–Baltimore</td>
</tr>
<tr>
<td>09:45</td>
<td>2136</td>
<td>Update on a new randomised adherence study</td>
<td>TSIRONI S–Thessaloniki</td>
</tr>
</tbody>
</table>
### FIRST MORNING SESSION

#### Emerald II  
**Doctor, I don’t like bright lights**  
Graham HOLDER, Bart LEROY  
**08:30 – 10:00**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>2141</td>
<td>The first consultation &amp; photophobia in anterior segment disease</td>
<td>HAWLINA M–Ljubljana</td>
</tr>
<tr>
<td>08:52</td>
<td>2142</td>
<td>Photophobia in ocular developmental disease</td>
<td>MOORE T–London</td>
</tr>
<tr>
<td>09:14</td>
<td>2143</td>
<td>Photophobia in inherited retinal disease</td>
<td>LEROY BP–Ghent</td>
</tr>
<tr>
<td>09:36</td>
<td>2144</td>
<td>The role of electrophysiology</td>
<td>HOLDER GE–London</td>
</tr>
</tbody>
</table>

#### Mediterranea I  
**Psycho - neuro - immunology and the eye**  
Johannes NEPP, Nadja KNOP, Erich KNOP  
**08:30 – 10:00**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>2151</td>
<td>Functional anatomy, innervation and immune regulation of the ocular surface</td>
<td>KNOP N, KNOP E–Hannover, Berlin</td>
</tr>
<tr>
<td>08:48</td>
<td>2152</td>
<td>Principles of psycho-immunological relations – Do they apply to the eye?</td>
<td>NEPP J–Vienna</td>
</tr>
<tr>
<td>09:06</td>
<td>2153</td>
<td>Psychosomatics and implications on clinics of patients with blepharospasm</td>
<td>RICHTER MÜSKSCH S, NEPP J, FUNK M–Vienna</td>
</tr>
<tr>
<td>09:42</td>
<td>2155</td>
<td>The eyes – Doors to the world</td>
<td>ECKER B, GERBER G, REINELT T–Vienna</td>
</tr>
</tbody>
</table>

#### Adria  
**FRO: Belgian Fund for Research in Ophthalmology 1**  
**08:30 – 10:00**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>2161</td>
<td>Topical cyclosporine in the treatment of vernal keratoconjunctivitis in a Rwandan eye clinic: a prospective, randomized, double-masked, clinical trial</td>
<td>DE SMEDT S–Gent</td>
</tr>
<tr>
<td>08:45</td>
<td></td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>08:50</td>
<td>2162</td>
<td>Structural and functional arterial properties in low-tension glaucoma</td>
<td>HEREMAN S–Gent</td>
</tr>
<tr>
<td>09:05</td>
<td></td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>09:10</td>
<td>2163</td>
<td>Correlation between visual field defects and fitness to drive in glaucoma patients</td>
<td>LELOUP E–Gent</td>
</tr>
<tr>
<td>09:25</td>
<td></td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td>2164</td>
<td>Serum markers in screening for regional and distant metastases in conjunctival melanoma patients</td>
<td>MISSOTEN G–Antwerpen</td>
</tr>
<tr>
<td>09:45</td>
<td></td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

### Keynote Lecture

**10:15 – 10:55**

**Europa A**

**Delivery of eye care in developing countries - Role of research**  
Gullapali RAO, Hyderabad - India  
Introduction by Jost JONAS  
**EVER 2007 programme**
## Europa A
**Free Papers: Immunology / Microbiology**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:39</td>
<td>2213</td>
<td>The antilymphangiogenic effect of aqueous humour</td>
<td>BOCK FB, ONDERKA JO, DIETRICH TD, BACHMANN BB, HOS DH, CURSIEFEN CC–Erlangen</td>
</tr>
<tr>
<td>12:03</td>
<td>2215</td>
<td>The Uveitis subtype associated with Spondylarthropathies varies regarding to gender and the type of Spondylarthropathy involved</td>
<td>MACKENBERG F, BECKER MD, MAX R–Heidelberg</td>
</tr>
<tr>
<td>12:15</td>
<td>2216</td>
<td>Epidemiology of severe uveitis in France: a prospective multicentre study</td>
<td>BODAGHI B, SANCHEZ-POTON A–Paris, Castres</td>
</tr>
<tr>
<td>12:21</td>
<td>2217</td>
<td>Interstitial uveitis: clinical course in ten years follow up</td>
<td>VIDOVIC VALENTINCIĆ N, KRAUT A, HAULINA M, STUNF S, ROTHova A–Ljubljana, Utrecht</td>
</tr>
</tbody>
</table>

## Europa B
**Genetics of non-mendelian complex eye diseases**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15</td>
<td>2221</td>
<td>Genes and gene-environmental interactions for retinal diseases</td>
<td>LIEW G–Sydney</td>
</tr>
<tr>
<td>11:33</td>
<td>2222</td>
<td>Genetics of corneal endothelial dystrophies</td>
<td>VITHANI EN–Singapore</td>
</tr>
<tr>
<td>11:51</td>
<td>2223</td>
<td>The genetics of refractive errors</td>
<td>YAP E–Singapore</td>
</tr>
<tr>
<td>12:09</td>
<td>2224</td>
<td>Familial correlations and gene-environmental interactions for myopia</td>
<td>SAW SM–Singapore</td>
</tr>
<tr>
<td>12:27</td>
<td>2225</td>
<td>Myopia genetics: lessons from other complex diseases</td>
<td>GUGGENHEIM JA–Cardiff</td>
</tr>
</tbody>
</table>

## Emerald I
**EURETINA: How does the laser work? The mechanism of retinal photocoagulation**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15</td>
<td>2231</td>
<td>Retinal photocoagulation: clinical aspects</td>
<td>BEK T–Aarhus</td>
</tr>
<tr>
<td>11:35</td>
<td>2232</td>
<td>The effect of laser on retinal oxygenation (animal studies)</td>
<td>POURIARAAS CG–Geneva</td>
</tr>
<tr>
<td>11:55</td>
<td>2233</td>
<td>Retinal oximetry in humans: effect of laser</td>
<td>HARDARSON SH–Reykjavik</td>
</tr>
<tr>
<td>12:15</td>
<td>2234</td>
<td>Physiological effects of vitrectomy and retinal laser treatment explain their clinical effects: Vitrectomy and laser treatment both affect retinal oxygenation and benefit ischemic retinopathies</td>
<td>STEFANSSON E–Reykjavik</td>
</tr>
<tr>
<td>12:35</td>
<td></td>
<td>Panel discussion</td>
<td></td>
</tr>
</tbody>
</table>

*EVER 2007 programme*
### Emerald II

**Free Papers: Vision Sciences / Electrophysiol. / Physiol. Optic**

**FP**

<table>
<thead>
<tr>
<th>11:15</th>
<th>2241</th>
<th>Optimal stimulus size maps in the primary visual cortex revealed by optical imaging in cats</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>CASANOVA C, VANNI M, VILLENEUVE MY–Montreal</td>
</tr>
<tr>
<td>11:27</td>
<td>2242</td>
<td>Mathematical analysis of the cone ERG photopic hill: Clinical applications</td>
</tr>
<tr>
<td>11:39</td>
<td>2243</td>
<td>Improvement of S-cone mediated visual fields and rod function after correction of vitamin A deficiency</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HAYASHI T, TAKEUCHI T, GOKKA T, KUBO A, NAKANO T, TSUNEOKA H–Tokyo</td>
</tr>
<tr>
<td>11:51</td>
<td>2244</td>
<td>Optical inhibition of axial myopia progression</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PHILLIPS JR, ANISTICE NS–Auckland</td>
</tr>
<tr>
<td>12:03</td>
<td>2245</td>
<td>Macular abnormalities and the Rarebit Fovea Test</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MARTIN L, NILSSON M, WANGER P–Stockholm</td>
</tr>
<tr>
<td>12:15</td>
<td>2246</td>
<td>Fixation stability during the Rarebit Fovea Test</td>
</tr>
</tbody>
</table>

### Mediterranea I

**Ocular movements: structural, functional and clinical aspects**

**SIS**

<table>
<thead>
<tr>
<th>11:15</th>
<th>2251</th>
<th>The dynamic cell biology of extraocular muscles</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>MCLAUNO L–Minneapolis</td>
</tr>
<tr>
<td>11:33</td>
<td>2252</td>
<td>Morphological variations found in human extraocular muscles and their functional implications</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BRUENECHE JR, KJELLEVOLD HAUGEN IB–Kongsberg</td>
</tr>
<tr>
<td>11:51</td>
<td>2253</td>
<td>The potential role of sensory receptors in ocular movements</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HAUGEN IBK, BRUENECHE JR–Kongsberg</td>
</tr>
<tr>
<td>12:09</td>
<td>2254</td>
<td>Orbicularis oculi muscle and eyelid movements in health and disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td>VAN DER WERF F–Rotterdam</td>
</tr>
<tr>
<td>12:27</td>
<td>2255</td>
<td>Neuromuscular junctions of human extraocular muscles: looking for new tools for medical treatment of strabismus</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PEDROSA DOMELLOF F, LIU JX, WILLISON HU–Umeå, Glasgow</td>
</tr>
</tbody>
</table>

### Adria

**FRO: Belgian Fund for Research in Ophthalmology 2**

**Joint M.**

<table>
<thead>
<tr>
<th>11:15</th>
<th>2261</th>
<th>Overcoming the barrier of the neural retina for the delivery of non-viral gene complexes to the retinal pigment epithelium</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>PEETERS L–Gent</td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td>Discussion</td>
</tr>
<tr>
<td>11:35</td>
<td>2262</td>
<td>Role of VEGF-isoforms in pathological angiogenesis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>VAN BERGEN T–Leuven</td>
</tr>
<tr>
<td>11:50</td>
<td></td>
<td>Discussion</td>
</tr>
<tr>
<td>11:55</td>
<td>2263</td>
<td>The role of the VEGF family in anti-angiogenesis and neurodegeneration in the retina</td>
</tr>
<tr>
<td></td>
<td></td>
<td>VAN DE VERE S–Leuven</td>
</tr>
<tr>
<td>12:10</td>
<td></td>
<td>Discussion</td>
</tr>
<tr>
<td>12:15</td>
<td>2264</td>
<td>Ex vivo expansion of human limbal epithelial stem cells for the treatment of corneal diseases with limbal stem cell deficiency</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ZAKARIA N–Antwerp</td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td>Discussion</td>
</tr>
</tbody>
</table>
**Europa A**  
**A Report from the International Dry Eye Workshop (DEWS)**  
14:00 – 15:30

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker(s)</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>Introduction by the moderators</td>
<td></td>
</tr>
</tbody>
</table>
| 14:12 | 2311 | Definition & classification of dry eye  
BRON AJ–Oxford |
| 14:25 | 2312 | The epidemiology of dry eye disease  
SMITH JA–Bathesda, MD |
| 14:38 | 2313 | Diagnostic methodology  
TOMLINSON A–Glasgow |
| 14:51 | 2314 | Clinical trial methodology in dry eye disease  
SCHAUMBERG D–Boston |
| 15:04 | 2315 | Management & therapy  
LEMP MA–Washington DC |
| 15:17 | 2316 | Report on research in dry eye  
GIPSON IK–Boston, MA |

**Europa B**  
**ARVO session: Mentoring: How, what, why and when**  
14:00 – 15:30

Who do you turn to for guidance? In the context of academic training as well as career development, the benefits of mentoring are clear. Successful individuals almost always have an informal network of colleagues they can turn to for help. Persons at the beginning of their career, when mentoring might be crucial, often have to fend for themselves. Here we will discuss the benefits of having a mentor. The speakers will give advice on how to find a mentor. There will also be talk about the rewards that come from being a mentor. Recognizing the need for mentorship, many academic institutions have established formal mentoring programs. The speakers will describe some of the elements of a successful institutional mentoring program. The first part of the session will focus on the mentoring for students and persons undergoing postdoctoral or fellowship training. After this, the emphasis will switch to mentoring during the process of career development. The third part of the session will be given to discussion of the special needs of clinician scientists who must juggle the clinic and the lab. With today’s communication opportunities a good mentor does not always need to be someone close at hand. Indeed, the very best mentor might be someone in a distant time zone. The speakers discuss ways ARVO and EVER can be used as a resource to find a mentor from among society members.

**Emerald I**  
**Glaucmatous optic neuropathy**  
14:00 – 15:30

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker(s)</th>
<th>Title</th>
</tr>
</thead>
</table>
| 14:00 | 2331 | An overview of the pathogenesis of glaucomatous optic neuropathy  
GUNGO K–Gaziantep |
| 14:22 | 2332 | Optic nerve injury models in the rat  
TUGLU I–Manisa |
| 14:44 | 2333 | Cell death in optic neuropathy  
VALENZUELA EG–Illinois |
| 15:06 | 2334 | Effects of primary open-angle glaucoma on the globe, cross sectional area and morphology of the optic nerve and volume of the lateral geniculate body: a longitudinal study  
CEZAYIRLI E, TUGLU I, GUNGO K, VAROL T, BEKIR N–Manisa |

**ACTA Lecture**  
15:45–16:25  
**Europa A**  
**The retinal pigment epithelium, friend or foe?**  
Morten la Cours, Glostrup - Denmark  
Introduction by Einar STEFANSSON
### Emerald II
**The nasolacrimal duct: Anatomy, diagnosis, surgery and nasolacrimal duct interventions, dacryocystoplasty - Part 1**

**14:00 – 15:30**

**SIS**
Zahra JAVDANI

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>2341</td>
<td>Dissectional and endoscopy of the lacrimal duct</td>
<td>JAVDANI Z, DENEF TE G, VERBIDDEN J-Mechelen</td>
</tr>
<tr>
<td>14:15</td>
<td>2342</td>
<td>Preoperative assessment before surgery of the lacrimal pathway</td>
<td>ELOY P, LEVECO L-Mont Godinne, Brussels</td>
</tr>
<tr>
<td>14:45</td>
<td>2344</td>
<td>External dacryocystorhinostomy</td>
<td>DUCASSE A-Paris</td>
</tr>
<tr>
<td>15:00</td>
<td>2345</td>
<td>Endoscopic endonasal dacryocystorhinostomy</td>
<td>ELOY P-Mont Godinne</td>
</tr>
<tr>
<td>15:15</td>
<td>2346</td>
<td>Non endoscopic endonasal DCR</td>
<td>MAVRIKAKIS I-Athens</td>
</tr>
</tbody>
</table>

### Mediterraena I
**Free Papers: Anatomy/Cell Biology 1**

**14:00 – 15:30**

**FP**
Erich KNOP, Saeed AKHTAR

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>2351</td>
<td>Antimicrobial peptides on the ocular surface in health and disease</td>
<td>Abedini A, Mohammd I, DUA HS-Nottingham</td>
</tr>
<tr>
<td>14:12</td>
<td>2352</td>
<td>Characterization within and around the Limbal Epithelial Crypt</td>
<td>Yeung AM, Schloetter Schreiat U, Kulikarni B, Hopkinson A, Kruse FE, DUA HS-Nottingham, Efkngen</td>
</tr>
<tr>
<td>14:24</td>
<td>2353</td>
<td>Gene expression profile of Limbal Epithelial Stem Cell niche</td>
<td>Kulikarni B, Yeung A, Hopkinson A, DUA HS-Nottingham</td>
</tr>
<tr>
<td>14:36</td>
<td>2354</td>
<td>Cytokeratin 8 and 18 expression in human corneal endothelium</td>
<td>Arbova K, Mejava S, Neuwitth A-Prague</td>
</tr>
<tr>
<td>14:48</td>
<td>2355</td>
<td>Difference of ocular injury by millimeter wave exposure with different frequency</td>
<td>Kojima M, Yamashiro Y, Sasaki H, Sasaki K-Kahoku-gun</td>
</tr>
<tr>
<td>15:00</td>
<td>2356</td>
<td>Remodelling of collagen fibrils and proteoglycans in the zebrafish cornea during development</td>
<td>Akhtar S, Schonthaler HB, Bron AJ, Dahm R-Oxford, Zurich, Vienna</td>
</tr>
</tbody>
</table>

### Adria
**Free Papers: Oncology / Pathology 1**

**14:00 – 15:30**

**FP**
Laurence DESJARDINS, Edoardo MIDENA

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>2361</td>
<td>Predicting the prognosis of ciliociliary uveal melanoma by its clinical characteristics: a European ophthalmic oncology group collaborative study</td>
<td>Kivelä T, Kulaia E, Desjardins L, Damato B, Bechrakis N, Grange JD-Helsinki, Paris, Liverpool, Berlin, Lyon</td>
</tr>
<tr>
<td>14:12</td>
<td>2362</td>
<td>Fish analysis of chromosome 3 and 6 on fine needle aspiration biopsy identifies distinct uveal melanoma subgroups</td>
<td>Parrozzo R, Bonaldi L, radin PP, Pilo To E, Midenica E-Padova</td>
</tr>
<tr>
<td>14:24</td>
<td>2363</td>
<td>Treatment of juxtapapillary choroidal melanoma</td>
<td>Missotten GS, Naus NC, Schal-U-Delvos NE, Luyten GP-Leiden, Rotterdam</td>
</tr>
<tr>
<td>14:36</td>
<td>2364</td>
<td>Matrix metalloproteinase-2 (MMP-2) is expressed in melanoma associated spongiform scleropathy (MASS)</td>
<td>Alayha GA, Kolko M, Prause JU, Heegaard S-Copenhagen</td>
</tr>
<tr>
<td>15:00</td>
<td>2366</td>
<td>Bilateral retinoblastoma: successful conservative treatment of both eyes</td>
<td>Hadustilianou T, De Francesca S-Siena</td>
</tr>
</tbody>
</table>
**Europa A**

**Free Papers: Keratoconus and corneal grafting**

17:30 – 19:00

17:30  2411  First experience with corneal collagen UV cross-linking treatment in keratoconus patients
MIKEK K, MORELA V-Ljubljana

17:42  2412  Wedge resection for high astigmatism in penetrating keratoplasty for keratoconus: refractive and histopathologic changes
DE LA PAZ MF-Bilbao

17:54  2413  Failure of topical Cyclosporine A 2% in patients with severe ocular rosacea after penetrating keratoplasty
GICQUEL J, BOURJES JL, LANGMANN ME, BONNERIC JO, RENARD O, DIGHEO PL-Paris

18:06  2414  Refractive and biomechanical changes with intrastromal ring segments for keratoconus

18:18  2415  Orbascan evaluation of keratoconus
HERNANDEZ VERDEJO J, CANADAS SUAREZ P, MARINA C, GARCIA-GONZALEZ M, TEUS MA-Madrid

18:30  2416  Corneal graft endothelial viability assessment using the triple labeling Hoechst/Ethidium homodimer/Calcein-AM: technical improvements using 3D microscopy
THURET G, PIPARELLI A, DUBARD S, PISELLI S, MURARME I, PEDEC H M, ACQUART S, ZHAO M, PRADES JM, DAIN PG-St-Etienne, Rouen

18:42  2417  A software system for automatic estimation of corneal epithelial cell density in confocal microscopy
RUGGERI A, GRIBAIX E-Padova

---

**Europa B**

**Free Papers: Genetics and animal models**

17:30 – 19:00

17:30  2421  A mutation in a novel connexin-like gene affects early lens development in the mouse
PUK O, LOESTER J, GRAV J-Neuherberg

17:42  2422  To see or not to see
DALKE C, FAVOR O, PUK O, GRAV J-Neuherberg

17:54  2423  The phenotype of retinal dystrophy in patients with DERR mutations
WILKE R, AIFA FERNANDEZ A, TAPIA I, GARCIA SANDOVA L, CATALAPIDEIRA D, VALLESPIN E, AYUSO C-Tuebingen, Madrid

18:06  2424  Genotype/phenotype features of the Slovenian patients with Stargardt disease: four novel mutations in ABCA4 gene and three novel complex alleles identified

18:18  2425  Mapping genomic loci related to variation in visual quantitative traits in an isolated island community of Croatia

18:30  2426  Autosomal dominant recurrent erosions – from non-existing to being everywhere
HAMMAR B, FAGERHOHLTMannP-Linkoping

---

**Emerald I**

**CONCORDIA: Promoting European Education in Ophthalmology**

17:30 – 19:00

17:30  2431  EBO promoting European Network Education
TASSIGNON MJ-President EBO

17:42  2432  EUPO: teaching the European residents in ophthalmology: history, 2007 and future
SPIELER W-Secretary General EUPO

17:54  2433  SOE and the young ophthalmologist
SEREZGD J-Secretary General SOE

18:06  2434  EVER: Research in ophthalmology and vision in Europe - Visions for the future
PLEYER U-President EVER 2007

18:18  2435  Increasing mobility in Europe with SOE and EBO grants
HAWKINA M-President Elest EBO

---

**Poster session 1**

16:30 – 17:25

**Europa C**

**Anatomy/Cell Biology - Cornea/Ocular Surface - Immunology/Microbiology - Molecular Biology/Genetics/Epidemiology - Vision Sciences/Electrophysiol./Physiol. Optic**

Luc MISSOTTON, Fatima PEDROSA DOMELLOF, Nadia KNOP - Jean-Jacques GICQUEL, Philippe KESTELYN - Bahram BODAGHI, Marko HAWLINA - Agnes FARKAS, Jez GUGGENHEIM - Bart LEROY, Pierre LACHAPELLE

Posters on pages 28-29
### Emerald II

**The nasolacrimal duct: Anatomy, diagnosis, surgery and nasolacrimal duct interventions, dacryocystoplasty - Part 2**  
17:30 – 19:00

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SIS</td>
<td>Nasolacrimal duct interventions-dacryocystoplasty (Balloon catheter dilatation in pre- and post sacculation obstructions)</td>
<td>Wilhelm K, Lachmuid U-Bonn, Zurich</td>
</tr>
<tr>
<td></td>
<td>Endoscopic dacryocystorhinostomy and balloon-dacryocystorhinostomy and transcanalicular DCR</td>
<td>Ungerercht R-Darmstadt</td>
</tr>
<tr>
<td></td>
<td>Overview of the lacrimal stents</td>
<td>Javadani Z, Valvanis A, Salu C, Lachmuid U, Wilhelm K-Mechelen, Zurich, Bonn</td>
</tr>
<tr>
<td></td>
<td>Treatment of epiphora in infants</td>
<td>Strn Kranac B-Ljubljana</td>
</tr>
<tr>
<td></td>
<td>Microsurgery of canaliculostenosis</td>
<td>Serra F-Antibes</td>
</tr>
</tbody>
</table>

### Mediterranea I

**ACB: Free Papers: Anatomy/Cell Biology 2**  
17:30 – 19:00

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FP</td>
<td>Oxidative stress in the trabecular meshwork – Preventive effects of Prostaglandin analogues</td>
<td>Welge-Luessen U, Yu AL, Kampilak A-Munich</td>
</tr>
<tr>
<td></td>
<td>Aldose Reductase Inhibition Counteracts Diabetes-Induced Retinal Oxidative Injury, Glial Activation, and Apoptosis</td>
<td>Obozova IG, Shih J, Lui TK, Julius U, El-Reemzy, A, Drel Vr-Baton Rouge, LA, Augusta, GA, Dresden</td>
</tr>
<tr>
<td></td>
<td>The localisation of erythropoietin and erythropoietin-receptor in the retinas of Goto-Kakizaki rats using immunohistochemical methods</td>
<td>Deak G, Szabo A, Seres A, Nemeth J, Szell A-Budapest</td>
</tr>
<tr>
<td></td>
<td>Prevention of hypoxia/reoxygenation- H2O2- and TGF-2 mediated increase of alphaB-crystallin and Hsp27 by the use of antioxidants</td>
<td>Yu AL-Munich</td>
</tr>
<tr>
<td></td>
<td>Bio-availability zinc in the outer segments of short wavelength cones</td>
<td>Lengyel I, Onwochei N-London</td>
</tr>
<tr>
<td></td>
<td>Metabolic stress as a contribution to physiological opening of TRP channels in blowfly (Calliphora vicina)</td>
<td>Perovsek D, Zupancic G-Ljubljana</td>
</tr>
<tr>
<td></td>
<td>Persistent pupillary membrane remnants attached to the anterior lens capsule</td>
<td>Chatzibalis T, Karaplatakis V, Ntampos K, Voutas S-Thessaloniki</td>
</tr>
</tbody>
</table>

### Adria

**In vivo micro-anatomy of the ocular anterior segment by confocal laser scanning microscopy**  
17:30 – 19:00

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SIS</td>
<td>Physical principles and recent developments in in-vivo confocal microscopy</td>
<td>Stachs O-Rostock</td>
</tr>
<tr>
<td></td>
<td>Implications of RLSM confocal laser scanning microscopy for the investigation of ocular anatomy</td>
<td>Knop E, Knop N-Berlin, Hannover</td>
</tr>
<tr>
<td></td>
<td>Distribution of dendritic cells in clinical differential diagnosis</td>
<td>Zheov V-Rostock</td>
</tr>
<tr>
<td></td>
<td>Alterations of conjunctival microanatomy in dry eye disease</td>
<td>Kraak R-Rostock</td>
</tr>
<tr>
<td></td>
<td>Anatomy of ocular lymphatic tissue in confocal laser scanning microscopy</td>
<td>Knop N, Knop E-Hannover, Berlin</td>
</tr>
<tr>
<td></td>
<td>Laser scanning IVCN of the limbus</td>
<td>Nubile M-Chieti Pescara</td>
</tr>
<tr>
<td></td>
<td>The corneal module of the HRT-II: A new tool for assessing ocular inflammation</td>
<td>Labbe A, Baudouin C-Paris</td>
</tr>
</tbody>
</table>
Anatomy/Cell Biology

Moderators:
Luc MISSOTEN, Fatima PEDROSA DOMELLOF, Nadja KNOP

201 Characterization of efflux proteins in human corneal epithelial cells
VELONEN KS, MANHERMAA E, TURNER H, TOROPAINEN E, URITTI A – Helsinki, Kuopio, New York

202 Bio-available zinc in the outer segments of short wavelength cones
LENGVEL I, ONIOCHEI N–London

203 Metabolic stress as a contributor to physiological opening of TRP channels in blowfly (Calliphora vicina)
PEROVSK M, PULAMCIC G – Ljubljana

204 Persistent pupillary membrane remnants attached to the anterior lens capsule
CHATZIBALI S, THARMATAKIS V, NIAMOS K, VOUTAS S – Thessaloniki

205 Interleukin1-Induced apoptosis of keratocytes: effect of biglycan
KOLUKOVA M, SHARPO A, FAGERHOLM P – Linköping, Riga

206 Role of EGFR in corneal remodelling in diabetes
AKHTAR SAEEED, IBRON AJ, YOUSIF M, BINTER IF, AKHTAR S –Dundet, Kuwait

207 Ghrelin expression in the iris and ciliary epithelium of fetal and newborn rats
ROCHA DE SOUSA A, MOURA RS, SARAVAJ L, AMARAL M, CORREIA P – Leiria, Portugal

208 Crolstalk of Hsp70 molecular chaperone, lysosomes and proteasomes in macroautophagy-mediated protolysis in human retinal pigment epithelial cells
RYHÄNEN J, HYTTLINEN J, KOPITZ L, MANHERMAA E, UUSITALO H, SALMINEN A, KAARMANTA K–Kuopio, Heidelberg

209 Effects of UDP on ARPE cells: possible involvement of P2Y6 receptors
JUDICE DE MENEZES REVAS I, BOUFFIOLUX C, MARCEP B, COMMUNI D, BIERO D, BRUYÈRES C, CASPERS L, BOEYNAS J, WILLERMANN F–Brussels

Cornea/Ocular Surface

Moderators:
Jean-Jacques GICQUEL, Philippe KESTELYN

210 Descemet membrane endothelial keratoplasty using descemetochorhexis and organ-cultured donor corneal tissue
MURAIINE M, GARDEA E, TOUBEAU D, BRASSEUR G – Rouen

211 Ultrastructure of Femtosecond Laser Transplantation for keratoplasty
VOSSMAYR-BAUMER U, KNOX MC, JONAS JB – Mannheim

212 Corneoscleral transplantation for extensive infection of the cornea
FRESINA M, CELLINI M, LEONETTI P, BENDO E, CAMPOS E – Bologna

213 NGF topical administration in dogs affected by spontaneous keratoconjunctivitis sicca
DOGI PL, ZANOTTI C, COSTA N, ALOE L – Parma, Forli, Catanzaro, Rome

214 Aberration control with contact lenses

215 Keratoctye repopulation in UVB-exposed thioltransferase knockout mice
PODSKOCZ A, ZHANG Y, HO YS, LÖFGREN S – Stockholm, Detroit

216 Corneo–conjunctival leukoplakia: histology and confocal microscopy
MALANDRINI A, FRUSCHELLI M, TRAVERSI C, MOLOTESE PA, MARTONE G, MOLOTESE E–Siena

217 Use of sodium hyaluronate “doughnut” in corneal gluing
SKINNER KC, MERRILL CD, GREGORY PYS, CHRONI FC – Hastings

218 Counting strategies for endothelial assessment of organ cultured corneas using image analysis: comparison of border versus center method

219 Development of an image analysis device to measure transparency, folding and gerontoxon of organ cultured corneas

220 Ocular surface in dry eye patients is improved after one month therapy with Systane
VERSIPA P, PROFAZO V, CAMPOS E–Bologna

221 Changes in the α1 – α4 collagen IV chains in the corneas of posterior polymorphous corneal dystrophy patients
MERAJIA S, LISKOVA P, JIRSJOVA K–Prague

222 4-PDD induces Ca2+ influx in human corneal epithelial cells by activating TRPV4 channels
MERSL J, PAN Z, YANG H, LUH H, TACHADO SD, ZHANG F, PLEYER U, RENJACH P – Berlin, New York, Cincinnati, Bath

223 Reconstitution of conjunctival epithelium under the influence of mesenchymal stem cells on a rabbit model of symblepharon
GARDEA E, GUEUDRY D, DUCLOS C, VANNIER JF, MARIE JP, LAMACZ M, MURAINE M – Rouen

224 Repair of corneal endothelium after mechanical damage under tissue culture and hypothermic conditions
NEJEPSKIN J, JIKULKO J, JIRSJOVA K–Prague

225 Effect of mitomycin C on epithelial hyperplasia after laser-assisted subepithelial keratectomy (LASER)
TEUL MA, DE BENITO-LLOPS L, ORTEGA M, EGUREN M, FERRER B–Madrid

226 Strong expression of matrix metalloproteinases in the molten corneas of rheumatoid arthritis patients
JIKULKO J, JIRSJOVA K–Prague

227 Changes in corneal surface aberrations after myopic INTRALASIK and LASER: Comparison between Technolas and Excimer
CANADAS SUAREZ P, ARRANZ E, GARCIA-RECIDIO C, VILLAFRANCA M, TEUL MA – Madrid

228 Visual outcome and corneal aberrometry after implantation of intracorneal ring segments (INTACS) for keratoconus
HERNANDEZ VERDEJO J, TARZ N, GIL-CAZONAL R, FUENTES I, TEUL MA – Madrid

229 Corneal backscatter after penetrating keratoplasty
PATEL SV, MCLAUGHLIN AV, BOURNE WM – Rochester, Minnesota

230 Corneal hysteresis in patients with corneal pathologies
HERDENER R, PFEIFFER R, LAUTBECH S, PACHE M – Freiburg

231 Effect of Mitomycin-C on the conjunctival goblet cell density after lasik
RODRIGUEZ AE, RODRIGUEZ-PRATS JL, MEZOUQDA G, ALIO J – Alicante

232 Proteomic analysis of conjunctival swab by mass spectrometry
MCGLIGAN V, GRAHAM JE, MOORE JE, MCMULLAN G, GRAHAM RL, BEIRNE RO, DOWNES SC, MOORE CB – Coimbra
Immunology/Microbiology
Moderators: Bahram BODAGHI, Marko HAWLINA

233 Epidemiology of severe uveitis in France: a prospective multicentre study
BODAGHI B, SANCHEZ-POTON A–Paris, Castries

234 Interstitial uveitis: clinical course in ten years follow up
VIDOVIC VALENTINIC N, KRAUT A, HAWLINA M, STUFIN S, ROTHOVA A–Ljubljana, Umeå

235 The effect of post-operative antibiotics on the ocular surface bacterial flora in cataract patients
MOORE JE, GRAHAM JE, BEIRNE RO, DOWNES SC, MOORE CB–Côte-d’Ivoire

236 Pathogen or commensal: a PCR based study of ocular surface bacteria in normal and dry eyes
GRAHAM JE, MOORE JE, XU J, MOORE JE, GOODALL E, DOOLEY J, DARTT DA, DOWNES S, MOORE T–Côte-d’Ivoire, Boston

237 Incidence of endophthalmitis after cataract surgery: standard diagnosis versus molecular diagnosis
BATAILLE L, FERRER C, RODRIGUEZ A, ABAO JL, ALIO J–Alcalá, San Juan de Alcalá

238 PCR identification of Rhizobium radiobacter in post-operative endophthalmitis

239 Antimicrobial treatment of presumed ocular tuberculosis
KOUPIRA/JOFF SK, CHIOUET CC, BOUILLET LB, ROMANET JP–Grenoble

240 Ocular inflammation secondary to syphilis infection
PUCH CP, CHIOUET CC, PAVESE PP, BOUILLET LB, ROMANET JP–Grenoble

241 Is AZOOR an autoimmune disease?
SEIDOV A, WIESCHER A, FIORE B, LANZI L, MAIER M, ZIMMERMANN P–Munich

242 Comamonas: a not so common agent in hydrogel contact lens wearers
LANGMAN ME, DISIERO PL, GIGUEL J–Poitiers

243 Recurrent giant chalazion in hyperimmunoglobulinemia E (Job’s) syndrome
PATTER P, BERRU J, CHENSA ML, LOI M, DORE S, PINNA A–Nuvo, Sassari

Vision Sciences/Electrophysiol./Physiol. Optic
Moderators: Bart LEROY, Pierre LACHAPELLE

253 Retinal vein occlusion signals a significant risk of mortality in the Beijing eye study
LIBOND T, XING L, LII W, WANG Y, YANG H, JONAS JB–Hamburg, Beijing, Mannheim

254 Phenotype characteristics of patients with Usher syndrome type 2
FARKAS A, LESICH B, VARGAN Y, VAMOS R–Budapest

255 Identification of a novel VMD2 mutation in Slovene family with best vitelliform dystrophy
JARIC-VIDMAR M, SLAIPAJ M, POPOVIC P, GLOAC D, HAWLINA M–Ljubljana

256 Gene expression changes associated with endothelial cell loss during corneal organ culture
HILLARY MC, TAYLOR AW, CARLEY F, ZAMBRANO I–Manchester

257 Development of lentiviral vectors for gene therapy for Usher syndrome type 1B
HASHIMOTO T, GROSBERG R, ZHANG XM, GIBBS D, LILLO C, AZARIAN SM, WILLIAMS D, YANG X–Los Angeles, CA, LA Jolla, CA

258 Mapping candidate genes for familial high myopia in a polish population
RYJANZIC MA, PODGURSUM-MUSBELAK M, MRUGACZ M, FRAZDENBAU A, LEAL SM, BEJANIA BA, GAJECKA M–Poznan, Lublin, Białystok, Houston, Spokane

259 Screening for diabetic retinopathy in a rural population with an iluminating non-mydriatic camera
GARCER CREUZOT C, BEYMAT J, ARNAVILLE S, CHARLES A, ASTRUC K, BRON AM–Dijon

Molecular Biology/Genetics/Epidemiology
Moderators: Agnes FARKAS, Jez GUGGENHEIM

244 Clinical management of congenital achromatopisia
PINELLO L, MAZZAROLO M, MAIMONE PE, SUPPEJA E, CALIBRONI P–Padua

245 Family with brittle cornea Syndrome
TOSCOUNIDJE IH, MCKEAG D, ALI U, LUTTTALL S, BLACK G, BONSHEK RE–Manchester

246 Correction of congenital ptosis using Ptose-up
ALAM-YAVOODDUI RI, AKOVA VA–Adana, Ankara

247 Proof of new collagen synthesis in lid skin in Er:YAG laser skin resurfacing with in-situ hybridization
BEITRAM M, DRINKOVIK-DLUP B–Ljubljana

248 Dazoendoonscopy: feasibility and value as diagnostic tool
WILKE M, KLAUS V, KAMPK A–Münich

249 Periorcular Er:YAG laser skin resurfacing in ablative, dual mode and smooth mode – a histological comparison
BEITRAM M, DRINKOVIK-DLUP B–Ljubljana

250 Frequency of headache and associated eye conditions in Congolese patients
KAIMO WA, KAIMBO D, MISOTJENT L–Kinshasa, Leuven

251 A model of paediatric eye screening program for educators
STOKANOVIC N, KOZIS NL, GOGAKI E–Thessaloniki

252 Visual acuity and use of eye care services in elderly population
LAVINEN A, KOXNIIN S, RUDANKO SL, MARTEIEN L, LAATKAINEN L, AROMAA A–Helsinki

260 Fixation stability during the Rarebit Fovea Test
NILSSON M, GRANATH H, WALHBERG M, WANGER P, BRAUTASET R–Stockholm, Linköping

261 Methodology of retinal straylight assessment
VAN DEN BERG TJ–Amsterdam

262 Which color vision test should be used in progressive cone dystrophy?
THAEDENS AAH, VAN LITH-VERHOEVEN JC, BERNAUTS MGL, KLAVER CCW–Rotterdam, Nijmegen

263 Comparison of chromatic macular ERG and multifocal ERG in diabetic macular edema
ARAKEYAN MA, BORDEVA YN, RYABEVA AA, SHAMSHINVA AM–Moscow

264 Functional characterisation of rats visual system following ocular ischemia by evoked potentials and retrograde transportation of retinal ganglion cells
JEHE T, WINGERT K, DIMITRIU C, MESCHEIDE W, LASSECK J, BACH M, LAGREZE W–Freiburg

265 Rarebit Fovea Test and OCT findings in diabetes
NILSSON M, VON WENDT G, WANGER P, MARTIN L–Stockholm

266 The influence of pupil size, accommodation and higher order aberrations on the retinal image of a Rarebit Fovea Test-stimulus
WALHBERG M, BRAUTASET R, UNBBO P, LUNDSKOG PETERSSON A, NILSSON M–Stockholm

267 Foveal function in children treated for amblyopia
AGERW PH, NILSSON MA, MARTIN LM–Stockholm

268 Macular function in severe diabetiocular amblyopia
SHAMSHINVA AM, IBMANDOVA NN, KHATOVEA NN, SITIKNOVA DN–Moscow

269 Correctable and non-correctable refractive error in a population of young men in Poland
NOWAK MS, GOS R, SIMGIELSKI J–Lodz

270 Functional characteristic of the retina in glaucoma
KAZARIAN AA–Moscow

271 Function of macular area in retinopathy of prematurity
SHAMSHINVA AM, KATARGINA LA, KOLOGLEVA LV, SITIKNOVA DN–Moscow
SOE 2009 THE 17TH CONGRESS OF THE EUROPEAN SOCIETY OF OPHTHALMOLOGY

SOE 2009, 13-16 JUNE 2009
AMSTERDAM, THE NETHERLANDS

NOG NEDERLANDS OOGheelKundig Gezelschap

www.soeso9.org

European University Professors of Ophthalmology EUPO 2008

Annual Residents’ Course
September 5-6, 2008 - Geneva, Switzerland
Organization: Prof. A.B. Safran, Geneva University Eye Clinic

Neuro-Ophthalmology and Strabismus
The course will provide an overview and an update on recent advances in the above topics.

Friday September 5, 2008
08:00 am - 06:00 pm, Neuro-Ophthalmology
EUPO Party

Saturday September 6, 2008
08:00 am - 06:00 pm, Strabismus

www.eupo.eu

Illustration: The Old Cloak, Van Dongen (1906)
Musée du Petit Palais - Genève

C O N C O R D I A : U n i t e d  i n  p r o m o t i

Thursday, October 4th -
European Board of Ophthalmology (EBO) Examination 2008 will take place on May 9-10th, 2008 at the:
Palais des Congrès de Paris
2, Place Porte Maillot
F-75017 PARIS
FRANCE

**When?**
May 9-10, 2008

**Where?**
Paris, Palais des Congrès (Porte Maillot)

**Application period**
From October 1, 2007 till January 1st 2008
Electronic application form (website)

**More information...**
http://www.ebo-online.org
Make your opinion count: attend the Section Business Meetings 19:00-20:00
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Europa A</strong></td>
<td><strong>Diagnostic imaging of the cornea</strong></td>
<td>08:30 – 10:00</td>
<td></td>
</tr>
<tr>
<td>08:30</td>
<td>SIS</td>
<td>Optical Coherence Tomography (OCT) and Ultrasonic Biomicroscopy in corneal diseases</td>
<td>NUBILE M–Chieti</td>
</tr>
<tr>
<td>08:52</td>
<td>3111</td>
<td>Corneal topography and aberrometry: contribution to the ocular surface to visual optics</td>
<td>VINCI GUGGERA P–Milano</td>
</tr>
<tr>
<td>09:14</td>
<td>3113</td>
<td>In vivo confocal microscopy of the cornea</td>
<td>GUTHOFF RF–Rotterdam</td>
</tr>
<tr>
<td>09:36</td>
<td>3114</td>
<td>Impression Cytology in corneal and ocular surface pathology</td>
<td>DUA HS–Nottingham</td>
</tr>
<tr>
<td><strong>Europa B</strong></td>
<td><strong>Free Papers: Retinal vascular disease</strong></td>
<td>08:30 – 10:00</td>
<td></td>
</tr>
<tr>
<td>08:30</td>
<td>FP</td>
<td>Quantitative fluorescein angiograms</td>
<td>SANTOS T, BERNARDES R, BAPTISTA P, SCHWARTZ A, CARTER W, CUNHA-VAZ J–Coimbra, San Juan, Groton</td>
</tr>
<tr>
<td>08:42</td>
<td>3122</td>
<td>Intermediate and combined forms of retinal telangiectasises</td>
<td>ZOGRAFOS L–Lasanne</td>
</tr>
<tr>
<td>08:54</td>
<td>3123</td>
<td>Prognostic tools for visual acuity in primary rheumatogenous retinal detachment</td>
<td>ROLBANI-PALLARES M, MUSA AS, BRAVO-LLATAS C, HERNANDEZ-MONTERO J, FERNANDEZ-DURANGO R–Madrid</td>
</tr>
<tr>
<td>09:06</td>
<td>3124</td>
<td>Microstructural changes of longitudinal retinal venous profiles measured by retinal vessel analyzer in systemic hypertension</td>
<td>KOTUAR KE, NAGEL E, SEIDOVÁ SF, LANZL IM–Munich, Rudolstadt</td>
</tr>
<tr>
<td>09:18</td>
<td>3125</td>
<td>Diagnosis and follow-up of retinal detachment using a wide field scanning laser opthalmoscope.</td>
<td>ARNDT CF, NABHOLZ N, BAZALGETTE C, NGUYEN N–Montpellier</td>
</tr>
<tr>
<td>09:30</td>
<td>3126</td>
<td>A new heavy internal tamponade in vitreoretinal surgery: an in vitro study</td>
<td>MICHELE L, FANINI D, FANTINI A, PAOLONI M, TOGNETTO D, RAVALICO G–Tesoro</td>
</tr>
<tr>
<td>09:36</td>
<td>3127</td>
<td>Profile of the Spanish ophthalmologist dedicated to retinal pathology. Preliminary results</td>
<td>SANCHEZ CHICHARRO DÍ, PASTOR ALMENO JC, FERNANDEZ I, ROJAS J–Valladolid</td>
</tr>
<tr>
<td><strong>Emerald I</strong></td>
<td><strong>Exfoliation and glaucoma</strong></td>
<td>08:30 – 10:00</td>
<td></td>
</tr>
<tr>
<td>08:30</td>
<td>SIS</td>
<td>Epidemiology and clinical findings of exfoliation syndrome</td>
<td>TSIROKIS S–Thessaloniki</td>
</tr>
<tr>
<td>08:48</td>
<td>3131</td>
<td>New insights into pathophysiology of exfoliation</td>
<td>SCHLOETZER SCHREHARDT U–Erlangen</td>
</tr>
<tr>
<td>09:06</td>
<td>3132</td>
<td>Blood flow changes in exfoliation</td>
<td>DAYANIR V, TOPALOGLOU A, OZBUNAR Y, KECELI M, OKYAY P, HARRIS A–Aydin, Indianapolis</td>
</tr>
<tr>
<td>09:24</td>
<td>3133</td>
<td>Current concepts in the management of exfoliative glaucoma</td>
<td>KONSTAS AGP–Thessaloniki</td>
</tr>
<tr>
<td>09:42</td>
<td>3134</td>
<td>Management of co-existing cataract and exfoliation</td>
<td>TEUS MA, DE BENITO-LOLIPIS L–Madrid</td>
</tr>
</tbody>
</table>
### Mediterranean I

**Animal models of ocular inflammation**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>3151</td>
<td>Experimental models of ocular inflammation: an overview</td>
<td>Bodagh B--Paris</td>
</tr>
<tr>
<td>08:42</td>
<td>3152</td>
<td>Regulation of ocular inflammation--what experimental and human studies have taught us</td>
<td>De SMET M--Antwerp</td>
</tr>
<tr>
<td>09:06</td>
<td>3154</td>
<td>Control of experimental uveoretinitis by specific or nonspecific regulatory T-cells</td>
<td>Terrada C, De Kozak Y, Lehoang P, Salomon B, Bodagh B--Paris</td>
</tr>
<tr>
<td>09:30</td>
<td>3156</td>
<td>Immunopathogenesis of corneal graft rejection</td>
<td>Pleyer U--Berlin</td>
</tr>
<tr>
<td>09:42</td>
<td></td>
<td>General discussion</td>
<td></td>
</tr>
</tbody>
</table>

### Adria

**Non-melanocytic conjunctival lesions**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>3161</td>
<td>Non-melanocytic conjunctival epithelial lesions: overview</td>
<td>Rosner M--Tel-Hashomer</td>
</tr>
<tr>
<td>08:45</td>
<td>3162</td>
<td>Long-term results of combined treatment with excision and cryosurgery for malignant epithelial tumors of the conjunctiva</td>
<td>Altan-Yayooglu R, Peysavar G, Onal S--Adana, Istanbul</td>
</tr>
<tr>
<td>09:10</td>
<td>3163</td>
<td>The response of squamous cell carcinoma of the conjunctiva to treatment with photodynamic therapy</td>
<td>Barbazetto IA, Lee TC, Abramson DH--New York, Los Angeles</td>
</tr>
<tr>
<td>09:35</td>
<td>3164</td>
<td>Topical 5-fluorouracil treatment and topical interferon alpha-2b treatment for conjunctival epithelial malignant lesions</td>
<td>Midena E--Padova</td>
</tr>
</tbody>
</table>

**Keynote Lecture**

10:15 – 10:55

**Europa A**

**Antigen-presenting cells and the eye**

Martine J Jager, Leiden - The Netherlands

President ARVO

Introduction by Charlotte ALL-ERICSSON
**Europa A**  
**Free Papers: Ocular surface and dry eye**  
Thomas WOOD, Jean-Jacques GICQUEL  

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Code</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15</td>
<td>3211</td>
<td>Densitometry of meibomian samples from normal and dry eye subjects</td>
<td>TIFFANY J, LAVRAC A–Oxford, Ljubljana</td>
</tr>
<tr>
<td>11:27</td>
<td>3212</td>
<td>Correlation between diagnostic tests guides the development and use of a dry eye diagnostic algorithm</td>
<td>MOORE JE, GRAHAM JE, GOODALL E, DARTT DA, LECOSOTTI A, DOWNES S, MOORE CBT–Coleaine, Boston, Siena</td>
</tr>
<tr>
<td>11:39</td>
<td>3213</td>
<td>Influence of platelets on the healing of dry eye of patients treated with topical eye drops of autologous Platelet-Rich Plasma (PRP)</td>
<td>BATAILLE L, ALIO J, PASTOR S, KLONOWSKY P–Alcante, San Juan de Alicante</td>
</tr>
<tr>
<td>11:51</td>
<td>3214</td>
<td>Nodular Degeneration</td>
<td>WOOD TO, WILLIAMS EE, HAMILTON DL–Germantown</td>
</tr>
<tr>
<td>12:03</td>
<td>3215</td>
<td>Watch out if you tell it with flowers: Euphorbia latex keratitis</td>
<td>LANGMAN ME, DIGHIERO PL, GICQUEL J–Potties</td>
</tr>
<tr>
<td>12:15</td>
<td>3216</td>
<td>Menstrual cycle influences ocular surface parameters in normal and dry eye patients</td>
<td>VERBURA P, PROFAZIO V, COSLOVI C, CAMPOS EC–Bologna</td>
</tr>
</tbody>
</table>

**Europa B**  
**Inherited retinal disease: novel developments and treatment strategies**  
Bart LEROY, Graham HOLDER  

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Code</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15</td>
<td>3221</td>
<td>Retinal dystrophies &amp; dysfunctions</td>
<td>LEROY BP–Ghent</td>
</tr>
<tr>
<td>11:37</td>
<td>3222</td>
<td>Macular dystrophies</td>
<td>MOORE T–London</td>
</tr>
<tr>
<td>11:59</td>
<td>3223</td>
<td>Treatment strategies</td>
<td>SAHEL JA–Paris</td>
</tr>
<tr>
<td>12:21</td>
<td>3224</td>
<td>Electrophysiology as a diagnostic tool</td>
<td>HOLDER GE–London</td>
</tr>
</tbody>
</table>

**Emerald I**  
**Intraocular pressure fluctuations in glaucoma: myth or reality**  
Nathalie COLLIGNON, Sanjay ASRANI  

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Code</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15</td>
<td>3231</td>
<td>Circadian rhythm of intraocular pressure in healthy subjects and glaucoma patients</td>
<td>ROMANET JP, PALOMBI K, NOEL C, CHIQUET C–Grenoble</td>
</tr>
<tr>
<td>11:33</td>
<td>3232</td>
<td>Large intraocular pressure fluctuations: a risk factor for glaucoma progression</td>
<td>ASRANI S–Durham, NC</td>
</tr>
<tr>
<td>11:51</td>
<td>3233</td>
<td>When the IOP zigzag are combined with abnormal dipping of the arterial pressure curve</td>
<td>COLLIGNON N, COLLIGNON J–Liège</td>
</tr>
<tr>
<td>12:09</td>
<td>3234</td>
<td>Diurnal IOP curve versus 24-hour IOP curve: when and how to do it in practice</td>
<td>KONSTAS AG–Thessalonikí</td>
</tr>
<tr>
<td>12:27</td>
<td>3235</td>
<td>Which glaucoma treatments best flatten the IOP fluctuations?</td>
<td>ORZALESI N, FOGAGNOLO P–Milan, Rome</td>
</tr>
</tbody>
</table>

**Europa A**  
**THEA lunchtime CIS: New evaluation techniques in ocular surface diseases**  

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Code</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:50</td>
<td></td>
<td>Introduction</td>
<td>Théa</td>
</tr>
<tr>
<td>12:55</td>
<td>3271</td>
<td>In vivo experimental evaluation of cornea using high frequency ultrasound device</td>
<td>PISELLA P–Boulogne</td>
</tr>
<tr>
<td>13:05</td>
<td>3272</td>
<td>The new imaging techniques for assessing ocular surface diseases</td>
<td>KRUSE FE–Erlangen</td>
</tr>
<tr>
<td>13:15</td>
<td>3273</td>
<td>A new experimental approach to early signs of eye irritation after acute and repeated exposures on HCE (in vitro reconstituted human corneal epithelium); an evaluation of effects of some multidose tear substitutes</td>
<td>MELONI M–Milano</td>
</tr>
<tr>
<td>13:25</td>
<td>3274</td>
<td>Comparison of antiallergic drugs using in vivo confocal microscopy for assessing late response of induced ocular anaphylaxis in the guinea pig</td>
<td>FERAILLE L–La Gaude</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Title</td>
<td>Presenter(s)</td>
</tr>
<tr>
<td>-------</td>
<td>---------</td>
<td>-------</td>
<td>--------------</td>
</tr>
<tr>
<td>11:15</td>
<td>Emerald II</td>
<td><strong>Duncan Symposium: Memory of George Duncan</strong></td>
<td>Alfred WEGENER, Giovanni MARAINI</td>
</tr>
<tr>
<td>11:15</td>
<td>3241</td>
<td>Foundations of lens ion transport</td>
<td>DELAMERE NA—Tucson, AZ</td>
</tr>
<tr>
<td>11:30</td>
<td>3242</td>
<td>Calcium, the Universe and Everything</td>
<td>SANDERSON J—Norwich</td>
</tr>
<tr>
<td>11:45</td>
<td>3243</td>
<td>Sigma-1 receptor: a pivotal role in lens cell survival</td>
<td>WANG L, DUNCAN G—Norwich</td>
</tr>
<tr>
<td>12:00</td>
<td>3244</td>
<td>Calcium signalling can be bad for you: thapsigargin and PCO prevention</td>
<td>WORMSTONE IM, WANG L, DUNCAN G—Norwich</td>
</tr>
<tr>
<td>12:15</td>
<td>3245</td>
<td>Growth factor signalling and regulation of lens cell differentiation</td>
<td>MCAVOY JW, STUMP RAW, ANG S, CHEN Y, LOVICU FJ—Sydney</td>
</tr>
<tr>
<td>12:30</td>
<td>3246</td>
<td>Alpha-Crystallins and their role in cataract and other diseases</td>
<td>HORWITZ J—Los Angeles</td>
</tr>
<tr>
<td>11:15</td>
<td>Mediteranea I</td>
<td><strong>Novel ophthalmic technologies V</strong></td>
<td>Tom MISSOTTEN</td>
</tr>
<tr>
<td>11:15</td>
<td>3251</td>
<td>Application of structured illumination techniques to corneal microscopy</td>
<td>REQUEJO-ISIDRO J, PEREZ-ESCUDEIRO A, MARCOE J—Madrid</td>
</tr>
<tr>
<td>11:33</td>
<td>3252</td>
<td>Three-dimensional high-speed optical coherence tomography for the investigation of the cornea and anterior eye-segments</td>
<td>YASUNO Y—Tsukuba, Ibaraki</td>
</tr>
<tr>
<td>11:51</td>
<td>3253</td>
<td>Optical coherence tomography of the choroid at 1050nm</td>
<td>UNTERHUBER A, POAZAZ B, HERMANN B, HOFER B, SATTMANN H, DREXLER W—Cardiff, Vienna</td>
</tr>
<tr>
<td>12:09</td>
<td>3254</td>
<td>Spectral domain OCT at 850 nm and OFDI at 1050 nm for retinal imaging in glaucoma and AMD patients</td>
<td>DEN BOER J—Boston</td>
</tr>
<tr>
<td>12:27</td>
<td>3255</td>
<td>Motion of the scattering sites in the ocular fundus during transpupillary thermotherapy</td>
<td>ROVATI L, CATTINI S, VIOLA F, STAUENGIH G—Modena, Milano</td>
</tr>
<tr>
<td>11:15</td>
<td>Adria</td>
<td><strong>The use of local chemotherapy in treating ocular malignancies</strong></td>
<td>Jacob PE’ER</td>
</tr>
<tr>
<td>11:15</td>
<td>3261</td>
<td>Treating ocular surface squamous neoplasia by topical Mitomycin C</td>
<td>FRUCHT-PERY J, PE’ER J—Jerusalem</td>
</tr>
<tr>
<td>11:30</td>
<td>3262</td>
<td>Treating conjunctival primary acquired melanosis with atypia by topical Mitomycin C</td>
<td>PE’ER J, FRUCHT-PERY J—Jerusalem</td>
</tr>
<tr>
<td>11:45</td>
<td>3263</td>
<td>Using local carboplatin in the treatment of retinoblastoma</td>
<td>DESJARDINS L—Paris</td>
</tr>
<tr>
<td>12:00</td>
<td>3264</td>
<td>Using intravitreal methotrexate for treating vitreoretinal lymphoma</td>
<td>PE’ER J, BIEGAL T, FRENKEL S—Jerusalem</td>
</tr>
<tr>
<td>12:15</td>
<td>3265</td>
<td>The potential of iontophoresis in introducing methotrexate and carboplatin into the eye</td>
<td>FRUCHT-PERY J, PE’ER J, DOMB AJ, ELJARRAT-BINSTOCK E—Jerusalem</td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td>Questions and discussion</td>
<td></td>
</tr>
</tbody>
</table>
**Europa A**

**Free Papers: Refractive surgery**

<table>
<thead>
<tr>
<th>Time</th>
<th>Paper ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>3311</td>
<td>Long-term results of LASIK in the correction of high myopia</td>
<td>LINDBOYM NM, TUISKU IS, TERVO TM–Helsinki</td>
</tr>
<tr>
<td>14:12</td>
<td>3312</td>
<td>Comparison of corneal aberrations after myopic LASEK and LASIK surgeries using two different excimer lasers</td>
<td>CANADAS SIAREZ P, HERNANDEZ-VIRUELO J, ROMAN-GUINDO J, SANCHEZ-PENA J, TEUS MA–Madrid</td>
</tr>
<tr>
<td>14:24</td>
<td>3313</td>
<td>Long-term stability of LASEK performed to correct myopia in thin corneas</td>
<td>TEUS MA, DE BENITO-LLOPIS L, ALVAREZ M, TORRES J, GIL-CIGANDA N–Madrid</td>
</tr>
<tr>
<td>14:36</td>
<td>3314</td>
<td>Stromal response to orthokeratology: an X-ray diffraction study</td>
<td>OWENS H, HAYES S, MEEK KM–Auckland, Cardiff</td>
</tr>
<tr>
<td>14:48</td>
<td>3315</td>
<td>Diclofenac effect on conjunctival goblet cells density after LASIK</td>
<td>RODRIGUEZ AE, RODRIGUEZ-PRATS JL, MEZQUIDA G, ALIO JL–Alicante</td>
</tr>
<tr>
<td>15:00</td>
<td>3316</td>
<td>LASIK dry eye: fact or fancy</td>
<td>REGINALD AV, TIFFANY JM, ROSEN PH, BRON AJ–Oxford</td>
</tr>
</tbody>
</table>

**Europa B**

**Free Papers: Antiangiogenic treatments**

<table>
<thead>
<tr>
<th>Time</th>
<th>Paper ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>3321</td>
<td>Placental growth factor (PIGF) inhibition reduces choroidal neovascularization in a mouse model for age-related macular degeneration</td>
<td>VAN DE VEERE S, MOONIS G, VINGROVES SA, CARMELEJ P, STALMANS I–Leuven, Baltimore</td>
</tr>
<tr>
<td>14:12</td>
<td>3322</td>
<td>Safety of Macugen (pegaptanib sodium) for neovascular age-related macular degeneration (NV-AMD): After 3 years of experience</td>
<td>LEYS A, VEGF INHIBITION STUDY IN OCULAR NEOVASCULARIZATION (VLS101.01)–Leuven</td>
</tr>
<tr>
<td>14:24</td>
<td>3323</td>
<td>The PERSPECTIVES Study: pegaptanib efficacy results in multicenter, open-label study (Phase 3b/4) of early CNV in neovascular AMD over time, including vision function and QoL endpoints</td>
<td>HEBEK L, PERSPECTIVES STUDY GROUP–Prague</td>
</tr>
<tr>
<td>14:36</td>
<td>3324</td>
<td>Anti-TNF-alpha therapy for exudative ARMD</td>
<td>MISGOTTEN T, BAARSSMA GS, VINGERLING JR, MARTINEZ-CIRIANO JP, VAN HAGEN PM–Rotterdam</td>
</tr>
<tr>
<td>14:48</td>
<td>3325</td>
<td>Intravitreal bevacizumab in the treatment of refractory uveitic macular edema-A one year follow up observational study</td>
<td>GALLAGHER MJ, CERVANTES-CASTANEDA RA, YILMAZ T, FOSTER CS–Boston</td>
</tr>
<tr>
<td>15:00</td>
<td>3326</td>
<td>Efficacy and safety of pegaptanib sodium for macular edema secondary to Central Retinal Vein Occlusion (CRVO)</td>
<td>WIROSTKO B, MACUGEN RETINAL VEIN OCCLUSION STUDY GROUP–Survey</td>
</tr>
</tbody>
</table>

**Emerald I**

**What can we do more? Neuroprotection in glaucoma**

<table>
<thead>
<tr>
<th>Time</th>
<th>Paper ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>3331</td>
<td>What have we learned about neuroprotection in the lab?</td>
<td>WHEELER LA, HARE WA, DONG CJ–Irvine</td>
</tr>
<tr>
<td>14:22</td>
<td>3332</td>
<td>How to watch ganglion cells in the DARC?</td>
<td>CORDEIRO MF–London</td>
</tr>
<tr>
<td>14:44</td>
<td>3333</td>
<td>How to monitor visual field progression?</td>
<td>VISWANATHAN A–London</td>
</tr>
<tr>
<td>15:06</td>
<td>3334</td>
<td>Does neuroprotection work in our patients?</td>
<td>GANDOLF S–Penza</td>
</tr>
</tbody>
</table>

**Keynote Lecture**

**15:45 – 16:25**

**Europa A**

**New perspectives in retinal imaging: fundus autofluorescence and age-related macular degeneration**

Frank G. HOLZ, Bonn - Germany

Introduction by Charles RIVA
Emerald II  Making sense of bilateral cataract surgery  Christopher LIU  14:00 – 15:30

14:00  3341  Making sense of immediately sequential bilateral phacoemulsification  LIU C-Brighton
14:22  3342  Biometry issues  SMITH G
14:44  3343  Disruption of binocular vision following cataract surgery  WHITE J-Brighton
15:06  3344  Health economics issues  LEIÓI T-Helsinki

Mediterranea I  Free Papers: Lens, Iris and Retina  Jan-Olof KARLSSON, Constantin POURNARAS  14:00 – 15:30

14:00  3351  Acute effects of the sigma-2 receptor agonist siramesine on lens epithelial cells  KARLSSON JO, JONHEIDE S, PETERSEN A, ZETTERBERG M–Göteborg
14:24  3353  The presence of an active ETB1 receptor is essential for ETB2 induced relaxation of the iris sphincter muscle  ROCHA DE SOUSA A, ALVES-FARIA P, SARAIWA J, AMARAL M, FALCAO-REIS F, LEITE-MOREIRA A–Porto
14:36  3354  TNF-alpha and Interferon-gamma upregulate AQP4 protein expression in ARPE-19, a human retinal pigmented epithelial cell line.  JANSSSEN S, CASPERS L, WILLERMAIN F, DELPORTE C–Brussels
14:48  3355  Efflux proteins of outer blood-retinal barrier  MAIINENMAA E, VOLENENI S, RYHÄNEN T, KAARININANTA K, URTTI A–Kuopio, Helsinki
15:00  3356  Erythropoietin (epo) and the survival of retinal cells in diabetic retinopathy  DE SOUZA RAMALHO P, PEREIRA DA SILVA A, BICHÓ MP–Lisbon

Adria  Free Papers: Oncology / Pathology 2  Charlotte ALL-ERDICSSON, Steffen HEEGAAARD  14:00 – 15:30

14:00  3361  Imaging of iris melanotic lesions and cemeal tumors with three different high speed optical coherence tomography instruments  DE KEIZER RW, RAZAZIQ L-Leiden
14:12  3362  Conjunctival melanoma & histone deacetylase inhibitors  MAIDAGN MC, CUNNEEN TS, NAREYECCK G, ANASTASSIOU G, CONWAY RM–Sydney, Essen
14:36  3364  Clinicopathologic analysis in nasolacrimal canal obstruction  ALTAN-YAVCIOLU R, CANAN H, BAL N, SIZMAZ S, PELOT A, AKSA YA–Adana, Ankara
15:00  3366  Lacrimal gland adenocarcinoma  GARCIA-ALVAREZ C, SANICHEZ-MANINARELLI F, BLANCO-MATEOS G, BORREGO H, ESTEBAN R–Valladolid
15:12  3367  Unusual recurrent orbital tumour  IRION LD, RONBIER H, ARAULLAH S, LEATHERBARROW B, MCEKEAG D, FERNANDO B–Manchester

Poster session 2  16:30 – 17:25
Europa C
Poster sessions on pages 44-45

Lens/Cataract - Pathology/Oncology - Retina/Vitreous
Jan-Olof KARLSSON, Alfred WEGENER - Jan Ulrik PRAUSE, Murat TUNC - Charles RIVA, Jean-Jacques DE LAEY, Einar STEFFANSSON
Europa A

**Free Papers: Cornea**

FP

Rimvydas ASOKLIS, Haminder S DUA

17:30  3411  Intracorneal bevacizumab for treating corneal neovascularization in an experimental rabbit model

17:42  3412  Amniotic membrane preservation in RPMI-1640 medium – 5 years experience
ASOKLIS R, BUTKiene L, JUDOKAITE G, MAKSELIS A, MONTVILAITE D – Vilnius

17:54  3413  Comparative analysis of donor derived, gene modified dendritic cells in keratoplasty
PLEYER U, SCHLIEKESER S, LI XQ, RITTER T, SAWITZKI B – Berlin, Galway

18:06  3414  A model for corneal endothelium specular microscopy images
BUCH C, SODERBERG JG – Stockholm

18:18  3415  rF  Descemet membrane endothelial keratoplasty using descemetoctomy and organ-cultured donor corneal tissue
MURAIINE M, GARDEA E, TOUBEAU D, BRASSEUR G – Rouen

18:24  3416  rF  Ultrastructure of Femtosecond Laser trephination for keratoplasty
VOSMEERBAEUMER U, KNORZ MC, JONAS JB – Mannheim

Europa B

**Retinal image analysis and quantitative fluorescein angiograms**

SIS  Rui BERNARDES, Alfredo RUGGERI

17:30  3421  A system to perform quantitative fluorescein angiography
SCHWARTZ A–San Juan

17:50  3422  Instrumentation adaptation for quantitative fluorescein angiograms
BERNARDES R–Coimbra

18:10  3423  Recent advances in the analysis of non vascular features in retinal images
RUGGERI A, RORIN D–Padova

18:30  3424  Advances in the detection of the retinal vasculature
HUNTER A, AL DIRI B–Lincoln

Emerald I

**Free Papers: Intraocular pressure and treatment**

FP

THIERRY ZEYEN, MONA PACHE

17:30  3431  Is corneal hysteresis an additional risk factor for glaucoma?
POURJAVAN S, BERIKOU K, DETRY- MOREL M – Brussels

17:42  3432  Comparison of Icare, dynamic contour tonometer, and ocular response analyzer with goldmann applanation tonometer
VANDEWALLE E, STALMANS I, Vandenbroeck S, ZEYEN T – Leuven

17:54  3433  Central corneal thickness and glaucoma in adult Chinese. The Beijing eye study
JONAS JB, XI L, ZHANG H, WANG Y–Beijing

18:06  3434  Monitoring individual compliance in glaucoma patients used to topical therapy
BRON AM, HERMANIN M, CREUZOT-GARCHER C, DIESTELHORST M–Dijon, Cologne

18:18  3435  Deep sclerectomy in normal tension glaucoma
SUOMINEN S, HAJU M, IHAMAKI T, VESTI E–Helsinki

18:30  3436  Trabeculectomy with or without adjustable flap sutures and anterior chamber maintainer
ZEYEN T, VANDEWALLE E, RENIER C, VAN DE VEIRE S, STALMANS I–Leuven

19:00 – 20:00  **Business Meetings of the scientific sections:**

**Agenda**

1. Report of the scientific officer
2. Report of the programme secretary
3. Next year’s meeting:
   • nomination of a section programme secretary
   • proposals of Special Interest Symposia (SIS)
4. Comment on the EER activities
5. Contact with Eastern Europe including Russia
6. Other business

In addition to the agenda, the sections Lens and Cataract and Retina / Vitreous will nominate candidates for scientific officer.
### Emerald II

**Oxidative stress in the lens**

**SIS**

**17:30** Introduction Marjorie F LOU by Per Söderberg

**17:35** 3441 Oxidation damage repair in the lens: Thioltransferae and Thioredoxin systems LOU MF–Lincoln

**17:55** Discussion

**18:00** 3442 Redox regulation of the proteasome in human lens epithelial cells and intact mouse lens PETERSEN A, CARLSSON T, CARLSSON JO, ZETTERBERG M–Göteborg, Malmö

**18:12** 3443 Enhanced diabetic cataract in mice lacking Cu-Zn superoxide dismutase OLOFSSON EM, MARKLUND ST, BEHNING A–Umeå

**18:24** 3444 Oxidative inactivation of the proteasome and its consequences in lens biology SHANG F–Boston

**18:36** 3445 Reduced and oxidized glutathione and TT-ase activity in mouse lens after in vivo exposure to ultraviolet radiation MEYER L–Stockholm

**18:48** 3446 Dose-response relationship for alpha tocopherol associated protection of ultraviolet radiation induced cataract WANG J–Stockholm

### Mediterranea I

**Free Papers: Bloodflow and oxygenation**

**FP**


**17:42** 3452 Effect of Travoprost and Brinzolamide on ocular hemodynamics STALMANS I, VANDEWALLE E, VANBELLINGHEN V, ZEYEN T–Leuven

**17:54** 3453 Effects of moxaverine and placebo on ocular blood flow GARHOFER G, RESCH H, WOLZT M, SCHMETTERER L–Vienna

**18:06** 3454 Patients with coronary heart disease show reduced dynamic retinal arterial reaction LANZL IM, ALI M, SCHMIDT-TRUCKSAESS A, HALLE M, PRESSLER A, KOTLIAR KE–Munich

**18:18** 3455 Oxygen gradients in the anterior segment of the eye REITSAMER HAR–Salzburg

**18:30** 3456 Retinal oxygen saturation in humans in light and dark HARDARSON SH, JÖNSSDOTTIR TE, BAYS B, HALDORSSON GH, KARLSSON RA, BEACH JM, EYESTEINSON T, BENEDIKTSSON JA, STEFANSSON E–Reykjavik

### Adria

**The anophthalmic socket**

**SIS**

**17:30** 3461 Exenteration: Indications, techniques, and results of treatment LEATHERBARROW B–Manchester

**17:42** 3462 Exenteration enucleation and evisceration: trends and dilemmas in pathology BONSHKE R–Manchester

**17:54** 3463 Strategies to prevent anophthalmic socket contraction in retinoblastoma patients TUNC M–Duzce

**18:06** 3464 Conditions for an ideal socket HAMEDANI M–Lausanne

**18:18** 3465 Retinoblastoma and the Anophthalmic socket reconstruction WILSHAW H–Birmingham

**18:30** 3466 Overview of therapeutics for improving the orbital volume in the socket syndrom MOURIAUX F–Caen

**18:42** 3467 Reconstruction of the congenital anophthalmic/cryophthalmic socket BRISCOE D, VARDZEER M–Kfar Saba, Haifa
Lens and Cataract

Moderators: Jan-Olof KARLSSON, Alfred WEGENER

301 Estimation of a safety limit for ultraviolet radiation-B (UVR-B)-induced cataract in an in vivo pigmented guinea pig model
MOODY VGC, KAKAR M, DONG X, ZHANG Y, HUANG S, GALICHANIN K, LÖFGREN S, SÖDERBERG PG—Stockholm

302 Age dependence of cataract induced by ultraviolet radiation-B in mice

303 Safety limits estimation for ultraviolet radiation induced cataract in different age groups
DONG X—Stockholm

304 A new universal rat restrainer for in vivo exposure to UVR without anesthesia
MOODY VGC, GALICHANIN K, HUANG S, ZHANG Y, MOODY L, LÖFGREN S, SÖDERBERG PG—Stockholm

305 Evolution of light scattering after in vivo close to threshold dose of ultraviolet radiation 360 nm
HUANG S, GALICHANIN K, MOODY V, LÖFGREN S, SÖDERBERG PG—Stockholm

306 Resolution visual fields in children surgically treated for congenital cataract
MARTIN M, MAGNUSSON G, POPOVIC Z, SŁOTYRANSKI J—Stockholm, Gothenburg

307 Modelling fluid mixing within the crystalline lens during accommodation
CHE S, HUNTER P, PHILLIPS JR, JACOBS M—Auckland

308 Ultrastructure features of lens epithelium in immature white cataract
STINF J, HVALA A, HAWLINA M—Lubljana

309 Modulation transfer function in refraction-defective multifocal intraocular lenses in vitro
PERIS-MARTINEZ C, ARTIGAS JM, MENEZ ROZALEN JL, FELIPE A, DIEZ AENJO A—Valencia

310 Evaluation of the performance of multifocal intraocular lenses image quality: analysis of the standard methods
MENEZ ROZALEN JL, ARTIGAS JM, FELIPE A, PERIS-MARTINEZ C—Valencia

311 High Order Aberrations of the eye implanted the Verisyse® iris-claw intraocular lens
GICOUEL JL, LANGMAN ME, NGUYEN KHDA A, MERCIE M, DIGHERO PL—Puteaux, Suresnes

312 Secondary IOL implantation without capsular support. A laser flare cell-meter study
BRAVETTI G, LEONETTI P, MANDRICHI M, STROBBLE E, CELLINI M, CAMPOS EC—Bologna

313 Pseudophakic dysphotopsia associated with the implantation of intraocular lenses
SKUNCA A, PETRIC VICKOVIC IP, LACMANOVIC LONCAR VIL, BEDINAR IB, DOKO MANIC BOM, MANICI Z—Zagreb

314 Pain in the different stages of cataract surgery by phacoemulsification technique in topical anaesthesia
KALMAN R, GOMBUS K, NAGY ZZ—Budapest

315 Anterior chamber depth changes and complications after Nd:YAG laser treatment for posterior capsule opacification in pseudophakic eyes
EVGINAN T, OZKURT Y, SENGÖR T, HABIBOGLU M, KURMA S, AKI S—Istanbul

316 Surgical outcome following iris related intraoperative difficulties in patients on tamulosin (Flomax) undergoing phacoemulsification
KANG CY, KHAN-LUM D, UNG I, LOCKWOOD A, FARWORTH D—Portsmouth, Southampton, Sheffield

317 Elastic modulus of the iris with drug stimulation
KOTLAR KE, WHITCOMB J, BARNETT V, OLSEN T, BAROCS V—Munich, Minneapolis

Pathology/Oncology

Moderators: Jan Ulrik PRAUSE, Murat TUNC

318 Ocular conservation in patients with uveal melanoma by a multimodality approach to treatment
GARCIA-ALVAREZ C, SAORIN MA, MUNOZ ME, ALMARAZ A, LOPEZ-LARA F, MUÑOZ Y, FRUTOS J—Valladolid

319 Quality assurance in episcleral brachytherapy

320 Immune expression and inhibition of HSP90 in uveal melanoma
FAINGOLD D, MARSHALL JC, ANTECKA E, DI CESARE S, BAKALIAN S, BURNER MN—Montreal

321 The effect of Blue-Light exposure in an ocular melanoma animal model
FERNANDES BE, DI CESARE S, MALONEY S, MARSHALL JC, DAWSON WW, BURNER MN—Montreal, Gainesville

322 AML with bilateral retinal detachment
SARKADY E, JONES NP, BONISHKE R—Manchester

323 Non Hodgkin orbital lymphoma
KNEVIZOVIC T, IVKOVIC R, MANIC D—Zagreb

324 Mechanisms of secondary glaucoma in eyes with advanced retinoblastoma; histopathological
HAJISTILIANOU T, FREZZOTTI P, MENICACCI F, MITRICA V—Siena

325 Autofluorescence and histological findings in cancer-associated retinopathy caused by small cell lung carcinoma
SKET KONTESTABLE A, BREGILJ I, PIZEM J, ADAMUS G, HAWLINA M—Lubljana, Oregon

326 Management of dumbbell-shaped dermoid cysts in the temporal fossa and orbit
MISSOTEN GS, DE KEIZER RW—Leiden

327 Oncocytic adenocarcinoma of lacrimal gland with GCDFP15 positivity
TOSOUNIDIS I, BONISHKE RE, LEATHERBARNW B, LANE C—Manchester, Cardiff

328 Silent squamous cell carcinoma invaded into the orbit via the perineural space of the trigeminal nerve

329 Use of Mitomycin C in the treatment of conjunctival and corneal squamous cell carcinoma, a case report
CELLINI M, LEONETTI P, STROBBLE E, CAMPOS EC—Bologna
Retina/Vitreous

Moderators:
Charles Riva, Jean-Jacques de laEy, Einar Stefantsson


333 The assessment of retinal layer thickness and volume segmentation reproducibility of optical coherence tomography images Tatrai E, Somfai GM, Ferenczi M, Puliayto CA, Cabrera FD – Budapest, Miami

334 Segmentation analysis of the age related retinal changes in patients with achromatopsia Varsaayi B, Lesch B, Vamos R, Farkas A – Budapest

335 The grey fovea sign of foveal or serous detachment on non-stereoscopic digital red-free fundus photographs Pascal Hasler, Solomon WS, Sanders BS, Haamann PH, Larsen ML – Glimstrup

336 The analysis of fundus autofluorescence patterns in retinal diseases Popovic P, Jarc - Vidmar M, Haulina M – Lubljana

337 Ocular and systemic factors associated with diabetes mellitus in the adult population in rural and urban china. The Beijing eye study Jonas JB, Xu L, Xie X, Wang Y – Beijing

338 Ultrastructure of diabetic epimacular tissue Synix S, Pac L, Synkova M – Brno

339 Correlation between fluorescein angiography and optical coherence tomography in diabetic macular edema Garcia Campos JM – Alcala

340 The sensitivity of OCT in the diagnosis of clinically significant macular edema van Duk HV, KOK PHB, Abramoff MD, Schlingemann RO, Bernardez R, Veerpraak FD – Amsterdam, Iota i, Combra

341 A preliminary study of cell therapy of diabetic retinopathy in mice with experimentally-induced diabetes Laziuk AV, Zemchikhina VN, Golubeva ON, Ernst LK, Budyleva IA – Moscow

342 Validity of non-mydratic cameras for screening and follow-up in diabetic retinopathy Ibanez J, Mateo A, Paure E, Cristobal JA, Del Buoy MA, Minguell E, Nunez E, Aescano FJ – Cangasur

343 Poster sub-tenon triamcinolone acetonide for the treatment of diabetic macular edema Ozkurt Y, Evcimam T, Habougl M, Sengor T, Kurnia S, Aki S – Istanbul

344 Association of single nucleotide polymorphisms (SNPs) of VEGF gene with diabetic retinopathy Linnamaa MA – Oulu

345 Intravitreal Tmacinolone Acetonide to control the diabetic macular edema Sanchez Chiocharro D, Lopez Galvez M – Valencia

346 Retinal layer thickness changes in eyes with diffuse diabetic macular edema Somfai GM, Tatrai E, Ferenczi M, Puliayto CA, Cabrera FD – Budapest, Miami

347 IL-8 vitreous levels in proliferative diabetic retinopathy Glogocnik Petrovic M, Kosnik M, Korosec P, Haulina M – Lubljana, Ljubljnik, Gostnik

348 Fundus autofluorescence pattern as risk factor for development of geographic atrophy in patients with age-related maculopathy Moessner A, Holz FG, FoA C – Leipzig, Bonn

349 Training improves the identification of Retinal Angiomaticosis Proliferation in the UK network of ophthalmic reading centres Paton WP, Petso T, Muldeyka W, Reeves B, Lenfesty P, Harding SP, Stevenson M, Chakravarty U – Belfast, London, Liverpool

350 Grading for progression of Age Related Macular Degeneration in the London AMD Study Peto T, Sallo F, Dandekar S, Leung I, Xing W, Bunce C, BRD AC – London

351 Glycopolymers of drusen and drusen-like lesions Bonshek RE, d’Ozoula Y, Jones C – Manchester, London

352 The role of telemedicine in improving the referral service for consideration of treatment for age-related macular degeneration in a tertiary referral centre d’Ozoula Y, Tuifal A – London

353 Risk factors for age related maculopathy in a Tunisian population El Mati L, Bouradji R, Baklouti K – Tunis, Nabeul

354 Full field ERG values before and after anti-VEGF treatment in AMD affected subjects Varno L, Campagna E, Russa C, Scorda V, Scordia GB, Brizzichesi D, Parsi E, Carnovalle Scalzo G, Scordia G – Catanzaro

355 Intravitreal bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes Ruiz Moreno JM, Montero- Moreno JA, Amat-Peral P, Lugo F, Staicu C, de la Vega C – Alcantar


357 Effects of autologous transplantation of the choroid and retinal pigment epithelium on the retinal light response in patients with neovascular age-related macular degeneration Lune C, Koch a, Kutzer J, Lune C, Dories J, Joussen AM, Kirchhof B – Cologna, Tbingen, Dasselord

358 A case of lead toxicity and associated maculopathy Pierce CO, Booth AA – Cosham


360 Foveal damage volume and visual acuity in solar retinopathy Lara Medina A J, Isba Callen C, Gonzalez del Valle FA – Alazar de San Juan

361 Results of optical coherent tomography in children with myopia Boychuk RM, Ivanivskaya EV – Odessa

362 Scleroplasty with posterior pole bucking for the treatment of high myopia Tarutia ER Markkeosan GA, Iomdina EN, Hachshenok ZH, Kruzikova GV – Moscow

363 Photodynamic therapy in myopic eyes with CNV with marked leakage Catalano C, Randazzo G, Parsi E, Scordia V, Scordia G – Catanzaro

364 The videosialotography effect of juxta-arterial microinjection of endothelin-A receptor inhibitor in healthy and in acute branch retinal vein occlusion Minipig Retina Pouarinas C, Stangos AN, Pouarinas AC, Petroopoulos IC – Geneva, Laosanne

365 Early treatment favours the anatomical outcome of ROP Boskos G, Kozis N, Rugantia S, Ageledou E – Thessaloniki


367 Thrombobiometricsad bilateral visual loss and in Bechet’s disease Dore S, Devilla M, Salvo M, Desolel L, Patteri P – Sassari, Nuoro

368 980 nm diode laser retinomotorial phacoaugmentation – in vitro comparison with frequency doubled Nd:YAG (532 nm) laser Ubrangic M, Medovic D, Pizam J, Dimovskoj Oup B – Lubljana

369 Trace elements in the retina of eyes enucleated due to complications of a severe trauma Iomdina EN, Filatova IA, Koroshevska EV – Moscow

10th anniversary congress

Saturday 6 October

Make your opinion count: attend the General Assembly & Prize Giving 18:05-19:00
**Europa A: Corneal transplantation: layer by layer**

**08:30**
- 4111 Reconstruction and replacement of the ocular surface
  DUA HS–Nottingham

**08:48**
- 4112 The DSAEK development and its modification for improved endothelial survival
  BUSIN I.A–Forli

**09:06**
- 4113 DLEK to DSEK to DMEK
  MELES GRI, ONG TS, VERVERS B, VAN DER WEES J–Rotterdam

**09:24**
- 4114 PKP versus LKP: rehabilitation speed, optical performance, endothelial cell loss
  KESTELYN P, CLAERHOUT I–Ghent

**09:42**
- 4115 The role of the Femtosecond (FS) laser in lamellar keratoplasty
  NJIITS MMIA, CHENG YY, PELS E, THE DUTCH LAMELLAR CORNEAL TRANSPLANTATION STUDY GROUP–Maastricht

**Europa B: ARMD: additional examinations critically reviewed**

**08:30**
- 4121 Fluorescein and ICG angiograms: still a gold standard
  O’TOOLE L–Dublin

**08:45**
- 4122 Reproducibility of OCT in choroidal neovascularization secondary to ARMD
  MENCHINI F, PARRAVANO C, ROMAN POGLIUZ D, MORGANTE L, VARANO M, BANDELLO F–Udine, Roma

**09:00**
- 4123 Phenotype-Genotype correlations: more than identifying risks?
  AUDO I, LEVEILLARD T, SAHEJ J–Paris

**09:15**
- 4124 Autofluorescence: additional value in clinical management of ARMD
  VACLAVIK V, BIRD AC–London

**09:30**
- 4125 Micropenetry: understanding what went wrong or predicting therapeutic routes
  VUJOSEVIC S–Rome

**09:45**
- 4126 (Multifocal) ERG: additional functional information in research and clinical settings
  TSANG SH, SANTOS R, GREENSTEIN VC–New York

**Emerald I: Free Papers: Diagnosis and progression**

**08:30**
- 4131 SITA-SWAP in glaucoma diagnosis
  MILANO G, BOSSOLESI L, MACERI C, COLOMBO M, BORDIN M, SERRA U–Pavia

**08:42**
- 4132 Accuracy of scanning laser polarimetry, scanning laser tomography in a glaucoma screening trial
  HOLLO G, GOTH M, KOHTY P–Budapest

**08:54**
- 4133 Cup reversal protects from glaucoma progression
  HARU M, SAARI J, KURVINEN L, VESTE E–Helsinki

**09:06**
- 4134 Combination of structural and functional methods for the diagnosis and follow-up of glaucoma: results of a two-year study
  SKORKOVSKA SS, MICHALEK JM–Brno

**09:18**
- 4135 Morphologic factors associated with progressive glaucomatous optic disc damage in patients with primary open angle glaucoma and low tension glaucoma
  LAEMMER R, HORN FK, JUENEMAIN AGM, MARDIN CY–Erlangen

**09:30**
- 4136 rF Structure-function relationship in the process of primary open-angle glaucoma - an OCT study
  AJTONY CS, BALLA ZS, KOVACS B–Pecs

**Ophthalmic Research Lecture**

10:15 – 10:55

**Europa A**

**Active subretinal implants in seven blind patients: outcome of a pilot study and further developments**

Eberhart ZRENNER, Tübingen - Germany

Introduction by Werner SPILEERS

Announcement of the winner of the inaugural European Vision Award

Details on page 59
Emerald II  **Ocular straylight measurement**  
SIS  Ralph MICHAEL, Tom VAN DEN BERG

**08:30**  4141  Basics of straylight in the human eye  
VAN DEN BERG TJJP–Amsterdam

**08:45**  4142  Glare as parameter of quality of sight  
TASSIGNON MJ, ROZEMA JJ–Antwerp

**09:00**  4143  Intraocular straylight and contrast sensitivity after LASIK  
MICHAEL R, OSPINO A, GIOINO J, RECANCOF A, BARRAQUER RI–Barcelona

**09:15**  4144  Straylight after cataract operation  
GRABNER G, MARVAN M–Salzburg

**09:30**  4145  Straylight induced by changes in the vitreous  
DE SMET M–Antwerp

**09:45**  4146  C-quant for clinical screening  
ASPINAL PA, DHILLON B, HILL AR, GRAVES R–Edinburgh

Mediterranea I  **ISCEV session**  
Joint M.  Colin BARBER

**08:30**  4151  The EVI-genoret phenotype / genotype patient data base: a pan-European tool for retinal dystrophies and age related macular degeneration  

**08:52**  4152  Electrophysiology and autofluorescence imaging in differential diagnosis of retinal and optic nerve disease  
HAWLINA M, JARC-VIDMAR M, POPOVIC P, BRECELJ J–Ljubljana

**09:14**  4153  Relationship between visual acuity, visual evoked patterned potentials done at different spatial frequencies and fundus findings in more than 100 Cerebral Visual Impairment affected subjects  

**09:36**  4154  A previously undescribed autosomal recessive retinal dystrophy  

Adria  **OOG: Papers**  
Joint M.  Edoardo MIDENA

**08:30**  4161  Atypical chalazion  
LOEFFLER K–Bonn

**08:40**  4162  Subcutaneous upper eyelid lesion  
LOEFFLER K–Bonn

**08:50**  4163  Monitoring cameo-conjunctival epithelial tumors: the in-vivo approach  
DE BELVIS V, MIDENA E–Padova

**09:00**  4164  Flow cytometry in the diagnosis of QAL  
RADNIN PP, MIDENA E–Padova

**09:10**  4165  Bilateral choroidal melanoma  
NOVAK ANDREJIC K, DRNOVICEK B, KRAUT A, MIDENA E

**09:20**  4166  Mapping conjunctival tumors: a prospective study  
DAMATO B, COUPLAND S–Liverpool

**09:30**  4167  Topical chemotherapy of conjunctival tumors: a reappraisal  
PEER J, MIDENA E–Jerusalem, Padova

**09:40**  4168  MLPA of extracocular tumors  
COUPLAND S, DAMATO B–Liverpool

**09:50**  4169  MLPA of uveal melanomas  
COUPLAND S, VAN DIJK M, SIBBIRING J, HOWARD P, DAMATO B–Liverpool
### Europa A
#### Keratoprosthesis 1

<table>
<thead>
<tr>
<th>Time</th>
<th>Paper Number</th>
<th>Title</th>
<th>Authors/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15</td>
<td>4211</td>
<td>Strampelli’s osteo-odonto-keratoprosthesis</td>
<td>BARRAGUER J, TEMPRANO J, DE LA PAZ MF–Barcelona</td>
</tr>
<tr>
<td>11:33</td>
<td>4212</td>
<td>UK experience and evolving strategies to improve results I - clinical results</td>
<td>PERERA S, OKERA S, TANDON R, HEROLD I, HULL C, THORP S, LIU C–Brighton</td>
</tr>
<tr>
<td>11:51</td>
<td>4213</td>
<td>UK experience and evolving strategies to improve results II - imaging</td>
<td>FRANCIS I, HEROLD, HULL, LIU C–Brighton</td>
</tr>
<tr>
<td>12:09</td>
<td>4214</td>
<td>OOKP - the Singapore Experience</td>
<td>WONG D, ET AL–Singapore</td>
</tr>
<tr>
<td>12:27</td>
<td>4215</td>
<td>Vitreoretinal management in osteo-odonto-keratoprosthesis surgery</td>
<td>WONG D–Singapore</td>
</tr>
</tbody>
</table>

### Europa B
#### Free Papers: Pathophysiology

<table>
<thead>
<tr>
<th>Time</th>
<th>Paper Number</th>
<th>Title</th>
<th>Authors/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15</td>
<td>4221</td>
<td>Why is geographic atrophy more common in Iceland than in other white populations.</td>
<td>JONASSON F–Reykjavik</td>
</tr>
<tr>
<td>11:39</td>
<td>4223</td>
<td>Reduced choroidal blood flow parameters play a role in the development of neovascular AMD</td>
<td>WEIGERT G, SCHMETERER L, LUKSCH A, MAAR N, ERGUN E, WIMPISINGER B, GARHOFER G, FUCHSJAEGER-MAYRL G, STUR M–Vienna</td>
</tr>
<tr>
<td>11:51</td>
<td>4224</td>
<td>Local and multifocal ERG in age-related macular degeneration.</td>
<td>ZOLNIKOVVA IV, AHMEDZAINOVA EV, KARLOVA IZ, SHAMSHINOVA AM–Moscow</td>
</tr>
<tr>
<td>12:03</td>
<td>4225</td>
<td>Human choroidal endothelial cell growth factor signalling in age-related macular degeneration</td>
<td>STEWART E, BROWNING AC, AMOAKU WIM–Nottingham</td>
</tr>
</tbody>
</table>

### Emerald I
#### Free Papers: Blood flow

<table>
<thead>
<tr>
<th>Time</th>
<th>Paper Number</th>
<th>Title</th>
<th>Authors/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15</td>
<td>4231</td>
<td>Variability of ocular perfusion measurements in glaucoma and healthy subjects</td>
<td>FUCHSJAEGER-MAYRL G, SCHMETERER L–Vienna</td>
</tr>
<tr>
<td>11:39</td>
<td>4233</td>
<td>Changed retinal capillary flow in patients with disc haemorrhages</td>
<td>KURVINEN L, HARju M, SAARI J, VESTI E–Helsinki</td>
</tr>
<tr>
<td>11:51</td>
<td>4234</td>
<td>Retinobulbar hemodynamics in normal tension glaucoma compared to anterior ischemic optic neuropathy</td>
<td>REMKY A, KAUP M, AREND KO, PLANIGE N–Aachen</td>
</tr>
<tr>
<td>12:03</td>
<td>4235</td>
<td>Disturbed vascular response of the central retinal artery during hypoxia in normal tension glaucoma</td>
<td>PLANGEN N, KAUP M, HARRIS A, AREND KO, REMKY A–Aachen, Indianapolis, Alsdorf</td>
</tr>
<tr>
<td>12:15</td>
<td>4236</td>
<td>Dynamic retinal vessel reaction in patients with primary open angle glaucoma</td>
<td>SEIDOVA SF, KOTLIAR KE, VON DURING C, LANZL I–Munich, Passau</td>
</tr>
</tbody>
</table>
### Emerald II

**Epidemiology of cataract**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15</td>
<td>4241 Quantitative cataract measurement SÖDERBERG P–Stockholm</td>
</tr>
<tr>
<td>11:27</td>
<td>4242 Quantification of light scattering and cataract development using the Scheimpflug's principle WEGENER AR–Bonn</td>
</tr>
<tr>
<td>11:39</td>
<td>4243 Cataract classification systems, a critical review SASAKI K–Uehnada</td>
</tr>
<tr>
<td>11:51</td>
<td>4244 Lens opacification in Icelanders 50 years and older, risk factors. Reykjavik eye study JONASSON F–Reykjavik</td>
</tr>
<tr>
<td>12:03</td>
<td>4245 Prevalence and risk factors of lens opacities in urban and rural chinese in Beijing JONAS JB, XU L, CUI T, ZHANG S, SUN B, ZHENG Y, HU A, LI J, MA K–Beijing</td>
</tr>
<tr>
<td>12:15</td>
<td>4246 Racial differences of lens transparency properties SASAKI H–Ishikawa-Ken</td>
</tr>
</tbody>
</table>

### Mediterranea I

**How to get your work published?**

**Workshop**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15</td>
<td>Uwe PLEYER, Pinar AYDIN, Andrew DICK, Jochen GRAW</td>
</tr>
</tbody>
</table>

Junior researchers often face the challenge of getting their interesting work published. The goal of this course will be to provide some keys to write a high quality paper that will help to transform innovative ideas into a research article. The presenters will discuss major aspects of the editorial process including basic decisions: where to submit your work, how to organize and prepare a manuscript, length of the review process, the revision process for re submission. The presenters will raise the discussion on issues like:

- How to choose a journal?
- How to organize your paper?
- What are the characteristics of a good manuscript?
- Delayed response: When is it appropriate to ask for the status of your manuscript?
- How to interpret the letter from the editor?
- How to write a good reply to the reviewers?
- What to do when your paper is rejected?
- When can it be appropriate to request a reevaluation of a rejected paper?

### Adria

**Tumours and tumour-like lesions of the optic nerve**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15</td>
<td>Jan Ulrik PRAUSE, Dan MILEA</td>
</tr>
<tr>
<td>11:17</td>
<td>4261 Disk swelling - differential diagnosis in orbital space occupying lesions GUTHOFF R–Rostock</td>
</tr>
<tr>
<td>11:33</td>
<td>4262 Neuro-ophthalmo logical analysis and imaging of optic nerve tumours MILEA D–Copenhagen</td>
</tr>
<tr>
<td>11:49</td>
<td>4263 The use of VEP in the evaluation of optic nerve lesions HOLDER GE–London</td>
</tr>
<tr>
<td>12:05</td>
<td>4264 Histopathology of optic nerve tumours HEEGAARD S–Copenhagen</td>
</tr>
<tr>
<td>12:21</td>
<td>4265 A rare case – a diagnostic challenge PRAUSE JU–Copenhagen</td>
</tr>
<tr>
<td>12:37</td>
<td>Closing remark by Dan MILEA</td>
</tr>
</tbody>
</table>
### FIRST AFTERNOON SESSION

#### Europa A  
**Keratoprosthesis 2**  
**SIS**  
Christopher Liu  
**14:00 – 15:30**

<table>
<thead>
<tr>
<th>Time</th>
<th>Paper ID</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>4311</td>
<td>Advances in the Type I Boston Keratoprosthesis</td>
<td>COLBY K, DOHLMANN C–Boston, MA</td>
</tr>
<tr>
<td>14:15</td>
<td>4312</td>
<td>Boston KPro collaborative study results</td>
<td>BELIN MW–Albany, NY</td>
</tr>
<tr>
<td>14:30</td>
<td>4313</td>
<td>An update on the AlphaCor</td>
<td>CRAWFORD G, HICKS C–Perth</td>
</tr>
<tr>
<td>14:45</td>
<td>4314</td>
<td>Where are we with the supra-Descemet KPro (KeraLia)?</td>
<td>LAMAR PD, ALFONSO E, STOIBER J, FERNANDEZ V, KAMINSKI S, LACOMBE E, DUCHESNE B, ACOSTA C, PAREL JM–Miami, Paris, Liège</td>
</tr>
<tr>
<td>15:00</td>
<td>4315</td>
<td>An update on the synthetic collagenous artificial cornea</td>
<td>FAGERHOLM P, GRIFFITH M–Linköping, Ottawa</td>
</tr>
<tr>
<td>15:15</td>
<td>4316</td>
<td>Infection control in KPros</td>
<td>NOURI M–Boston</td>
</tr>
</tbody>
</table>

#### Europa B  
**Retinal pigment epithelium**  
**SIS**  
Kai KAARNIRANTA, Hannu UUSITALO  
**14:00 – 15:30**

<table>
<thead>
<tr>
<th>Time</th>
<th>Paper ID</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td></td>
<td>Opening by Hannu UUSITALO</td>
<td></td>
</tr>
<tr>
<td>14:10</td>
<td>4321</td>
<td>Retinal pigment epithelial cells under oxidative stress</td>
<td>WELGE-LUSEN U–Munich</td>
</tr>
<tr>
<td>14:30</td>
<td>4322</td>
<td>Cellular responses to lysosomal dysfunction in RPE cells</td>
<td>KOPITZ J–Heidelberg</td>
</tr>
<tr>
<td>14:50</td>
<td>4323</td>
<td>Proteolysis in RPE cells</td>
<td>KAARNIRANTA K–Kuopio</td>
</tr>
<tr>
<td>15:10</td>
<td>4324</td>
<td>Regulation of complement activation in ocular and vascular inflammation</td>
<td>SEPPO M–Helsinki</td>
</tr>
</tbody>
</table>

#### Emerald I  
**Neuro-ophthalmic foibles**  
**Workshop**  
Aki KAWASAKI, François-Xavier BORRUAT  
**14:00 – 15:30**

<table>
<thead>
<tr>
<th>Time</th>
<th>Paper ID</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>4331</td>
<td>Clinical look-a-like</td>
<td>KAWASAKI A–Lausanne</td>
</tr>
<tr>
<td>14:22</td>
<td>4332</td>
<td>Misinterpretation of common ophthalmic tests</td>
<td>BORRUAT FX–Lausanne</td>
</tr>
<tr>
<td>14:44</td>
<td>4333</td>
<td>Radiologic pitfalls in neuro-ophthalmology</td>
<td>MILEA D–Copenhagen</td>
</tr>
<tr>
<td>15:06</td>
<td>4334</td>
<td>Management misadventures</td>
<td>BOSCHI A–Brussels</td>
</tr>
</tbody>
</table>
### Emerald II

**Wavefront aberrometry and adaptive optics**

Jean-Jacques GICQUEL

14:00 – 15:30

<table>
<thead>
<tr>
<th>Time</th>
<th>Code</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>4341</td>
<td>The basics of wavefront aberrometry</td>
<td>LANGMAN ME, DIGHERO PL, GICQUEL J-P, Politiens</td>
</tr>
<tr>
<td>14:18</td>
<td>4342</td>
<td>Applications of adaptive-optics in ophthalmology</td>
<td>CHATEAU N–Orsay</td>
</tr>
<tr>
<td>14:36</td>
<td>4343</td>
<td>Sports and wavefront aberrometry</td>
<td>GICQUEL J-P, DIGHERO PL, Politiens</td>
</tr>
<tr>
<td>14:54</td>
<td>4344</td>
<td>Limitations of correcting aberrations with soft contact lenses</td>
<td>LOPEZ-GIL N, CASTEJON-MICHON JF, BONAQUE S–Murea, Segovia</td>
</tr>
<tr>
<td>15:12</td>
<td>4345</td>
<td>Wavefront guided custom ablation: facts and fiction</td>
<td>NGUYEN KHÓA J–Pans</td>
</tr>
</tbody>
</table>

### Mediterranea I

**Matrix metalloproteinases in vascular and ocular disease**

Leopold SCHMETTERER

14:00 – 15:30

<table>
<thead>
<tr>
<th>Time</th>
<th>Code</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>4351</td>
<td>MMPs in vascular disease</td>
<td>WOLTZ M–Vienna</td>
</tr>
<tr>
<td>14:22</td>
<td>4352</td>
<td>MMPs in ocular physiology</td>
<td>EICHHORN M–Erlangen</td>
</tr>
<tr>
<td>14:44</td>
<td>4353</td>
<td>MMPs in CNV</td>
<td>LAMBERT V, RAKIC JM, NOEL A, FOYDART J–Liège</td>
</tr>
<tr>
<td>15:06</td>
<td>4354</td>
<td>MMPs in glaucoma</td>
<td>SCHLOETZER SCHREHARDT J–Erlangen</td>
</tr>
</tbody>
</table>

### Adria

**OOG: Protocols**

Joint M. Edoardo MIDENA

14:00 – 15:30

<table>
<thead>
<tr>
<th>Time</th>
<th>Code</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>4361</td>
<td>Choroidal tumor biopsy: a prospective case series</td>
<td>KHURSHID G, COUPLAND S, DAMATO B–Liverpool</td>
</tr>
<tr>
<td>14:15</td>
<td>4362</td>
<td>Endoresection of choroidal melanoma after proton beam radiotherapy</td>
<td>KHURSHID G, GROENWALD C, DAMATO B–Liverpool</td>
</tr>
<tr>
<td>14:30</td>
<td>4363</td>
<td>In vivo prognostication of posterior uveal melanoma: cost effectiveness and clinical value of different molecular tests</td>
<td>PARROZZANI R, MIDENA E–Padova</td>
</tr>
<tr>
<td>14:45</td>
<td>4364</td>
<td>An European protocol for the detection and treatment of high risk uveal melanoma</td>
<td>DESJARDIN L, COUTURIER J, PIPERNO-NEUMANN S–Paris</td>
</tr>
<tr>
<td>15:00</td>
<td>4365</td>
<td>Correlation between ultrasonographic tumor data and peritumoral subretinal fluid findings with OCT for the early detection of small malignant melanocytic tumors</td>
<td>GRANGE JD, GARNIER S, JEAN-LOUIS B, ABI-AVAD N, KODIKIAN L</td>
</tr>
<tr>
<td>15:15</td>
<td>4366</td>
<td>Validating the Helsinki University Central Hospital (HUCH) working formulation for staging metastatic uveal melanoma</td>
<td>ESKELI S, PIPERNO-NEUMANN S, DESJARDIN L, SCHMITTEL A, BECHRAKIS N, MIDENA E, GRANGE JD, RACT-MADOUX G, MARSHALL E, DAMATO B, LEYVRAZ S, ZOGRAFOS L, KIVELÅ–Helsinki</td>
</tr>
</tbody>
</table>

### Poster session 3

*Euroopa C*  
*Posters on pages 56-57*

**Neuro-ophthalmology / Strabismology / Paediatric Ophthalmology / History - Glaucoma - Physiology / Biochemistry / Pharmacology**

Lene MARTIN, Tulin BERK - Gabor HOLLO, Michèle DETRY - Leopold SCHMETTERER, William STEWART
### Second afternoon session

**Europa A**

**Corneal cross linking**

**Time:** 16:30 – 18:00

<table>
<thead>
<tr>
<th>Time</th>
<th>Code</th>
<th>Presentation</th>
</tr>
</thead>
</table>
| 16:30 | 4411 | Corneal Cross Linking  
SEILER T–Zurich |
| 16:41 | 4412 | Aspects of safety of riboflavin-UVA crosslinking of the cornea  
SPOEL E, MROCHEN M–Dresden, Zurich |
| 16:52 | 4413 | Corneal molding and crosslinking  
BARRAQUER RI, LAMARCA L, SALVADOR B, ALVAREZ DE TOLEDO JP–Barcelona |
| 17:03 | 4414 | Riboflavin/Ultraviolet a corneal collagen Cross-Linking: one year results  
ROSETTA P, VINCIUIGUERRA P, ALBE E–Milano |
| 17:14 | 4415 | Ocular response analyzer findings in keratoconic eyes undergoing Cross Linking procedure  
ALBE E, VINCIUIGUERRA PV, ROSETTA P–Milano |
| 17:25 | 4416 | Crosslinking in iatrogenic keratectasia after LASIK: pregnancy-related exacerbation  
HAFEDI E SEILER T–Zurich |
| 17:36 | 4417 | Micromorphological analysis of cross-linked cornea by in vivo scanning laser  
MAZZOTA C, CAPOROSI A, BAIOCCHI S, CAPOROSI O–Siena |
| 17:47 | 4418 | Mid term results in keratoconus treatment by Riboflavin – UVA corneal collagen Cross-Linking, Siena eye cross project  
CAPOROSI A, BAIOCCHI S, MAZZOTA C, CAPOROSI T–Siena, Rome |

**Europa B**

**Free Papers: Diabetic macular edema**

**Time:** 16:30 – 18:00

<table>
<thead>
<tr>
<th>Time</th>
<th>Code</th>
<th>Presentation</th>
</tr>
</thead>
</table>
| 16:30 | 4421 | Diabetic retinopathy screening with nonmydriatic fundus camera(1 and 3 fields) vs ETDRS standard  
MASSIGNANI F, VIUOVEVIC S, BENETTI E, PILOTTO E, MIDENA E–Padova, Roma |
| 16:42 | 4422 | Diabetes related complications – the Moorfields Diabetes Survey  
PETO T, LEUNG I, HARRIS N, XING W, BUNGE C–London |
| 16:54 | 4423 | Retinal fixation in Diabetic Macular Edema  
BOTTEGA E, VIUOVEVIC S, PILOTTO E, MIDENA E–Padova, Roma |
| 17:06 | 4424 | Decreased OCT measured central retinal thickness in patients with and without minimal diabetic retinopathy  
KOK PH, VAN DIJK HW, BIALLOSTERSKI C, VAN VELTHOVEN ME, VERBAAK FD–Amsterdam |
| 17:18 | 4425 | Difference in laser treatment decisions for diabetic macular edema, based on biomicroscopy or OCT  
VERBAAK F, VAN DIJK H, KOK PHB, SCHLINGEMANN RO, ABRAMOFF M–Amsterdam, Iowa City |
| 17:30 | 4426 | Two-year follow-up of patients with Diabetic Macular Edema (DME) treated with pegaptanib (Macugen)  
MEHRA S, MACUGEN DIABETIC RETINOPATHY STUDY GROUP–New York |

**Emerald I**

**Free Papers: Neuro-ophthalmology / Strabismology / Paediatric / History**

**Time:** 16:30 – 18:00

<table>
<thead>
<tr>
<th>Time</th>
<th>Code</th>
<th>Presentation</th>
</tr>
</thead>
</table>
| 16:30 | 4431 | Correlation between saccadic parameter variations and clinical evidences in thyroid autoimmune ophthalmopathy (TAO) affected patients  
| 16:42 | 4432 | Methods for quantifying diplopia  
HOLMES JM, HATT SR, LESKE DA, ADAMS WE–Rochester, MN |
| 16:54 | 4433 | The development of psychiatric disease in young adults who had childhood strabismus  
MOHNEY BG–Rochester |
| 17:06 | 4434 | Neural and behavioral mapping of the visual field in true and simulated visual field deficits  
KOZAK LR, SZATMARY G, VIDNYANOSZKY Z–Budapest |
| 17:18 | 4435 | A case of 2 brothers with congenital horners syndrome  
PIERCE CO, BINCJAJ N, EVANS A–Coahm |
| 17:30 | 4436 | Harry Moss Traquair (1875-1954) – Scottish ophthamologist and perimetricist  
GRZYBOWSKI A–Poznani |
SECOND AFTERNOON SESSION

FREE PAPERS: Optic nerve and sclera

16:30 – 18:00

Mediterranea I  
Neville OSBORNE, Selim ORGUL

16:30  4451  Ocular hemodynamic effects of nitrovasodilators in healthy subjects  
POLSKA E, KISS B, KOCH B, SCHMETTERER L–Vienna

16:42  4452  Optic nerve reflectivity variations during diffuse luminance flicker stimulation  
BONAUTI M, ROVATI L, RIVA CE–Modena, Bologna

16:54  4453  Minocycline is cytoprotective in human trabecular meshwork cells and optic nerve head astrocytes by increasing expression of XIAP, Survivin and Bcl-2  
KERNT M, NEUBAUER AS, YU AL, KAMPIK A, WELGE-LUSSEN U–Munich

17:06  4454  Support for the idea that light is a risk factor in optic neuropathies, like glaucoma  
OSBORNE NIN–Oxford

17:18  4455  Effect of induced myopia on scleral mechanics and myofibroblast populations  
BACKHOUSE S, BUMSTED O’BRIEN K, PHILLIPS JR–Auckland

17:30  4456  Topical beta-blockers and the risk of cardiovascular mortality  
AASONIUS NJM, WOLFS ROW, WITTEMAN JC, HOFMANS A, DE JONG FTVM, STRICKER BHC, MUSKENS RPHM–Groningen, Rotterdam, Amsterdam

Adria  
Eduardo MIDENA

OOG: Business meeting

16:30 – 18:00

- Minutes of the last meeting: approval
- EVER-OOG relationship
- OOG sessions (during other meetings)
- OOG 2008 spring meeting
- New members
- Annual fee and financial report
- TBA

General Assembly

EVER General assembly and prize giving

18:05 – 19:00

Europa A

Agenda
1. President’s address
3. Report of the General Secretary
4. Report of the Programme Secretary
5. Report of the Treasurer, approval of the accounts 2006, discharge to the directors, budget for 2007
6. Newsletters ; EVER Journal
7. Results of the elections
8. Presentation of the BOARD 2007-2008
9. President Elect, Vice President Elect
10. Categories of membership
11. Presentation and report of the scientific sections meetings
12. Future congresses
13. Prize giving
14. Miscellaneous

Social

EVER Farewell dinner

with musical entertainment by Mia Znidaric (vocal) and Steve Klink (piano)

EVER 2007 programme
POSTER SESSION 3 — 15:35 - 16:25 — EUROPA C

---

**Neuro-ophthalmology/Strabismology/ Paediatric ophthalmology / History**

**Moderators:**
Lene MARTIN, Tulin BERK

---

401 Optic radiation damage can be assessed directly by tractography
YAMAMOTO T, YAMADA K, PLANT GT—Kumamoto, Kyoe, London

402 Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency in anterior ischemic optic neuropathy
PINTA A, MASIA C, SOLINAS G, ZINELLI A, CARTA A—Sassari, Panna

403 Diagnosis and follow-up in patients with optic neuritis by means of optical coherence tomography (OCT) and scanning laser polarimetry (GDx)
EGEYA ESTUPINAN MC, PLEYO ROYO V, GUERR N, SANCHEZ CANO A, FERNANDEZ TIRADO FJ, RABIN M, ARBUES E, HONRUBIA FM—Zaragoza

404 Ocular motility disorders in a Fabry patient
LANZI L, MAIER M, ZIMMERMAN P, HAEFLE V, FIORE B—Munich

405 Visual function vs. spastic quadriplegia & brain damage
KAPOSI A, KOZES N, BOOSIK G, MOSCHOU V, LAKE S—Thessaloniki

AGGELOUDI A, KOZES N, STOJANOVIC N, KAPOSI A—Thessaloniki

407 Could vision prognose cerebral palsied children’s development?
TIGANITA S, KOZES N, KKONKOU D, LAKE S, GEORGIAIDIS N—Thessaloniki

408 Visual function vs. spastic diplegia & brain damage
GOGAKO EG, KOZES N, FEKEDUS A, GEORGIAIDIS N—Thessaloniki

409 Peculiarties of pupil reactions in patients with hyperopic amblyopia in dependence of monocular fixation
BUSHUJEVA NL, BOYCHUK IM, KHRANEKO NI, SHAKIR DURHIE MH—Odessa

---

**Glaucoma**

**Moderators:**
Gabor HOLLO, Michèle DETRY

---

410 Dynamic retinal vessel reaction in patients with primary open angle glaucoma
SEIOVA SF, KOTIJAR KE, VON DÜNING C, LANZI L—Munich, Passau

411 Abnormal peripheral vascular response to occlusion provocation in normal tension glaucoma patients

412 Structure-function relationship in the process of primary open-angle glaucoma – an OCT study
AZTONY CS, BALLA ZS, KOVACS B—Pécs

413 Glaucoma progression with GDx-VCC
TOTH M, HILLO G—Budapest

414 Outcome and risk factors for failure of primary trabeculectomy
MEDVED N, CVAEDEL B—Ljubjana

415 Treatment of patients with late complications after filtering surgery
BEDNIAR I, LACMANOVIC LONCAR V, KONJEVIC-PEINAR I, MANDIC Z—Zagreb

416 Ultrasound biomicroscopy in non penetrating filtration surgery with 5-Fluorouracil and without implant; long-term results
GUTIERREZ C, VELIEN E, PAREJA J, BOUVAR G, TEUS MA—Madrid

417 Trabeculectomy and Mitomy cin C (Trab-MMC) for uveitic glaucoma: post surgical interventions
LOCKWOOD A, SII F, CHANG M, WILLIAMS TA, SHAH P—Birmingham

418 Long term outcome of bleb needling revisions following mitomycin C trabeculectomy in Afro-Caribbean eyes
WILLIAMS TA, CRONBY N, SII F, CHANG M, LOCKWOOD A, SHAH P—Birmingham

419 Intravitreal bevazucimab for neovascular glaucoma
ANDRIEVIC DERK B, MANDIC Z, BENOIC G, VATAVUK Z, NOVAK-LAUSK K—Zagreb

---

420 Is nonadherence with eye drop treatment associated with increased intra ocular pressure?
VANDENBOECK S, DOBRELL F, DE GEEST S, STALMAN I, ZEYEN T—Leuven

421 Adjunctive use of tafuroprost with timolol provides additive effects for reduction in intraocular pressure in patients with glaucoma
EGOROV E, ROPO A—Moscow, Helsinki

422 The IOP-lowering efficacy of once-daily Tauroprost (Timolol) dosed in the morning compared to twice-daily Dorzolamide /Timolol for patients with open-angle glaucoma or ocular hypertension
HOLO G, LAGANOVSKA G, VOLKSOLE L, TEUS MA—Budapest, Riga, Madrid

423 The influence of selective laser trabeculeoplasty on diurnal intraocular pressure in POAG
KOTYH P, TOHT M, HILLO G—Budapest

424 Nyhetemoral rhythm of intraocular pressure in normal tension glaucoma
RENARD ER, PALOMBI KP, CHIQUET CG, PIPIN AP, NOEL CN, ROMANET JP—Genoble

425 Ophthalmoscopic estimation of cup-to-disc ratio and its relation to the evening intraocular pressure in normal individuals
CHATZIBALIS T, KARAMPATSAKIS V, GIKKA M, BENIOS A—Thessaloniki

426 Effectiveness of intraocular pressure phasing
ARIR FARS, HARDING A, HENSON D, SPENCER F—Hanford, Manchester

427 Short-term influence of antiglaucomatous medications on the ocular pulse amplitude (OPA) measured with the dynamic contour tonometer Pascal® DETRY-MOREL M, JAMART P, FOURJARAN S—Brussels, Yvoir

428 The comparison of the quality score of IOP and ocular pulse amplitude (OPA) values measured by dynamic contour tonometer
BOGHOSIAN P, BERKOU K, DETRY- MOREL M, FOURJARAN S—Brussels

429 Dynamic contour tonometry in corneal oedema
RENNINGS CA, PLANGE N, KAUP M, REMYK A—Aachen

430 Comparison of DCT, GAT and OPA values in patients with glaucoma
BREDFOR L, LAUBE-BACH S, HERDNER S, REINHARD T, PACHE M—Freiburg

431 Correlation between ocular response analyzer (ora) and dynamic contour tonometer (pdt) parameters in normal subjects and in glaucoma patients
EHONGO A, DE MARAELS V, COLLIGON N, FOURJARAN S—Brussels, Liège

432 Are pacchymetric and tomometric asymmetry related?
ALEMANY MARQUEZ P, JIMENEZ-CARMONA S, FAILLE I, CARRAF F, JORDANO J—Cadiz

433 Influence of diabetes on central corneal thickness in type II ocular hypertensive patients
JIMENEZ-CARMONA S, ALEMANY MARQUEZ P, FAILLE I, CARRAF F, JORDANO J—Cadiz

434 Correlation between global indices of short-wavelength automated perimetry and GDx VCC parameters
FERRERAS A, PAARIN AB, LARROSA JM, POLO V, BORQUE E, HONRUBIA FM—Zaragoza

435 Diagnostic ability of GDx VCC to discriminate between healthy eyes, ocular hypertensive subjects and glaucoma patients
BORQUE E, FERRERAS A, POLO V, LARROSA PAVE JM, ALIAS ALEGRE EG, BORQUE RODRIGUEZ E—Zaragoza

436 Correlations between retinal nerve fiber layer measurements obtained with the GDx VCC and standard automated perimetry
LOPEZ MJ, FERRERAS A, POLO V, LARROSA PAVE JM, ALIAS ALEGRE EG, BORQUE RODRIGUEZ E—Zaragoza

437 Evaluation of clinical and HRT II quantitative parameters to detect suspect and early glaucoma patients
SANCHEZ CANO A, GUERR N, EGEEA ESTUPINAN MC, PEREZ OLIVAN S, PABLO JUZLE LE—Zaragoza

438 Visualisation of reverse pupillary block using AC-OCT in primary pigment dispersion syndrome
LAERMER R, MAIRON CY, JUENENBERG AGM—Ehtingen

439 Diagnostic coincidence of the technologies of analysis of image HRT, OCT and GDx-VCC
ALIAS EG, BORQUE E, LARROSA JM, POLO V, FERRERAS A, HONRUBIA FM—Zaragoza
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors/Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>440</td>
<td>Influence of optic disc size in retinal nerve fiber analysis by OCT -- could a customizable circular algorithm help to solve the problem?</td>
<td>Reichini M, Scordion V, Scordion GB, Carnovale Scalzo G, BruzziChessi D, Scordion G-Catananzo</td>
</tr>
<tr>
<td>442</td>
<td>The impact of clinical variables on the visual field damage of patients with pseudoexfoliative glaucoma</td>
<td>Martínez-García A, Sánchez-Salorio M-Santiago de Compostela</td>
</tr>
<tr>
<td>444</td>
<td>The prevalence of glaucoma and ocular hypertension in a population of Polish young men</td>
<td>Nowak MS, Gos R, Kuybiak AB, Smigieliski J-Lodz</td>
</tr>
<tr>
<td>445</td>
<td>Elevated levels of 3-Nitrotyrosine (3-NT) in human eyes with primary open-angle glaucoma (POAG)</td>
<td>Fernández-Durango K, Fernández-Martínez A, García Feudo A, Martínez de la Casa JM, Fernández-Cruz A-Arnedo</td>
</tr>
<tr>
<td>447</td>
<td>Experimental glaucoma development in albino rabbits</td>
<td>Guerri N, Egea Estopinan MC, Garcia MA, Perez-Olivan S, LOU JM-Zanaga, Huesca</td>
</tr>
<tr>
<td>449</td>
<td>FDT Matrix 24-2 threshold strategy for the evaluation of glaucoma suspects and ocular hypertensive patients</td>
<td>Michelone L, Trovarelli S, Madonna M, Da Pozzo S, De Lauro MT, Sorce G, Ravalugo G-Hene</td>
</tr>
</tbody>
</table>

**Physiology/Biochemistry/Pharmacology**

**Moderators:** Leopold SCHMETERER, William STEWART

| 451     | Use of Travalex® in routine clinical practice | STEWART WC, JASEK MC, STEWART JA-Forth Worth, Charleston |
| 452     | Local tolerability of Timolol 0.5% / Travoprost 0.004% (Durotrav) fixed combination in patients with open-angle glaucoma | Pece G, Reichini M, Catalano C, Scordion V, Carnovale Scalzo G, Scordion G-Catananzo |
| 453     | Pharmacokinetics of preserved and preservative-free formulations of tafluprost are comparable in healthy volunteers | Ustiaulka H, Kairnoarmanta A, Rojo A-Curopo, Helsinki |
| 454     | Reduction in intraocular pressure is equivalent between preserved and preservative-free formulations of tafluprost | Hamacher T, Arakasinen J, Richter U, Rojo A-Starnberg, Oulu, Regensburg, Helsinki |
| 455     | In vitro comparison of the oxidative and proapoptotic effects of preserved latanoprost, travoprost, bimatoprost and preservative-free tafluprost on conjunctival epithelial cells | Braschi E, Brigoile-Baudouin F, Fianchi L, Guenoun JM, Warnet JM, Baudouin C-Paris |

| 456     | Short-term effect of topical bromidine tartrate on intrastratal pressure. an animal study | Bolivar G, Teus MA, Gutierrez CGO, Castanjon MA-Albacete de Henares |
| 457     | Neuropeptide y protects retina neural cells from estatyla-induced neurotoxicity | Ambrosio AF, Alvaro AB, Martin F, Fernandes E, Bastos ML, Carvalho F, Cavadas C-Coimbra, Porto |
| 458     | The suppression of early angiogenic markers by the antiangiogenic aptamer Macugen® is dose dependent | Bourgourd Pecko B, Koukouvioka M, Fagerholm P-Linkoping |
| 460     | Histopathological findings after intravitreal injection of Linezolid | Alcocer Yuste P, Perez Martin C, Avino-Martinez J, Vila C-Valladolid |
| 461     | Photodynamic therapy with Verteporfin combined with intravitreal injection of Bevacizumab for central serous choriorretinopathy | MANER M-Munich |
| 462     | Ocular and systemic distribution, and excretion of radioactivity following topical ocular administration of 14C-TG100801 to pigmented rabbits | Strubell C, Chiodini R, Martin M-Madison, San Diigo |
| 463     | Intravitreal treatment with Erythropoietin (EPO) preserves visual function following ocular ischemia in rats | Derch RD, Jehee TL, Meschede WM, Dimitru CI, Bach MB, Lagreze WL-Freiburg |
| 464     | Relation of crystallin and ischemia/Reperfusion injury model of the rat retina | Yang Yung WH, Jeonggun B, Soo CH, Jeek Chung CHUNG, Huntage--Icksan |
| 465     | Methylprednisolone (MP) failed to protect retinal ganglion cells and visual function following ocular ischemia in rats | Dimitriu C, Jehee T, Meschede W, Lassec J-B, Bach M, Lagreze W-Freiburg |
| 466     | Effects of (-)beutecoline and gamma-aminoxybutyric acid on the nicot/C mediated stimulation of the ERG b-wave amplitude from the isolated superfused vertebral retina | Schneide T, Sakep S, Banat M, Hecheler J, Lüke M, Schneide T-Köl, Tuebingen |
| 467     | Arabinogalactan: a new ophthalmic vehicle for dry eye protection and treatment of corneal lesions | Burghal S, Nicora N, Monti F, Dallone G, Boldrini E, Chetoni P-Peras, Pisa, Coro DI Forniigine |
| 468     | Ocular surface time and extensions of TFBUT of a lubricating eye drop | IPRAZAR UNDRARRAZA M, OUSLER III GW, SCHINDLER MR, PAULIG J-Barcelona, North Andover (MA), Follton (CA) |
| 469     | Nicardipine inhibits human conjunctival fibroblast proliferation, migration and attachment in vitro | Gonzalo IBannez E, Fuertes Fernández I, Laguierre Roncal L, PINILLA LOZANO I-Estella, Pampilma, Zanaga |
| 470     | Comparative study of commercially available antiasthmatic drugs in an animal model of drug phase allergic conjunctivitis | Montoro-Moreno JA, Sanchez-Menio ME, Ruiz-Moreno JA, Lugo F, ANMAT-PERAL, P DE LA VEGA C-Albinte, Valtadoll |
| 473     | Characterization of COX-1 and -2 inhibition by nepafenac and its metabolite, amfenac | KULMecz RJ, Graff G-Houston, Fort Worth |
European Vision Award
by the European Vision Institute EEIG // www.europevisioninstitute.org

The winner of the inaugural European Vision Award will be announced in a private reception during the EVER 2007 Congress on Friday, October 5, 2007, 18:30 h and again, open for the EVER public, on Saturday, October 6, 2007, 10:55 h after Professor Eberhart Zrenner’s keynote lecture. The ceremony takes place in room EUROPA A.

The European Vision Institute’s mission is to support programs and projects that develop, integrate and conduct vision research to prevent and treat eye diseases as well as to develop new therapeutic strategies to improve the quality of life for those suffering.

www.europevisioninstitute.org

The EVA 2008 European Vision Award

Information about the 2008 European Vision Award and application is available on the website.

The European Vision Institute is currently accepting applications for membership. Please visit the website for more information.

www.europevisioninstitute.org
INDEX — PRESENTING FIRST AUTHORS

ABU EL ASRAR A: 1356
AGERVI PH: 267
AGGELIDIOY A: ... 10:15
LA COUR, M: Thursday, 15:45
JAGER, MJ: Friday, 10:15
HOLZ, F: Friday, 15:45
ZRENNER, E: Saturday, 10:15
This programme book is organised chronologically

Four digit numbers refer to oral presentations

Day | Timeslot | Room | Order in session

Three digit numbers refer to posters

Day | Order in the poster session

The sessions are colour-coded

<table>
<thead>
<tr>
<th>Special Interest Symposium (SIS)</th>
<th>Keynote Lecture</th>
<th>Workshop</th>
</tr>
</thead>
<tbody>
<tr>
<td>Free Papers</td>
<td>General Assembly &amp; Business Meeting</td>
<td>Poster Session</td>
</tr>
<tr>
<td>Joint Meeting</td>
<td>Courses</td>
<td>Social</td>
</tr>
<tr>
<td>Commercial Interest Symposium</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

FP = Free Paper session  SIS = Special Interest Symposium  rf = Rapid Fire presentation
CIS = Commercial Interest Symposium  ☺ = Travel grant recipient

Scientific sections

ACB = Anatomy/Cell Biology  COS = Cornea/Ocular Surface
G = Glaucoma  IM = Immunology/Microbiology
LC = Lens and Cataract  MBGE = Molecular Biology/Genetics/ Epidemiology
NSPH = Neuro-ophthalmology/Strabismology/ Paediatric Ophthalmology/History of Ophthalmology
PBP = Physiology/Biochemistry/Pharmacology
PO = Pathology/Oncology  RV = Retina/Vitreous
This year EVER celebrates its 10th anniversary and would like to take the opportunity to thank all companies for their support during the first decennium.

Due to this support EVER can continue to encourage research and dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange of information.

EVER wishes everyone of its past and present sponsors good future for the coming years and thanks especially the following companies, many of which are our long-term supporters, for their generous sponsorship to the 10th congress.
**WEDNESDAY, Oct 4, 2007**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speakers</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>COS: A Report from the International Dry Eye Workshop</td>
<td>S. Atherington, N. Delamer, T. Libson</td>
<td>Europe A</td>
</tr>
<tr>
<td>14:00</td>
<td>Opening concert: Zorn Predin, acoustic guitar - Zorn Shizka piano</td>
<td></td>
<td>Europe A</td>
</tr>
<tr>
<td>19:00</td>
<td>EVER Welcome reception</td>
<td></td>
<td>on St. Bernardin terrace</td>
</tr>
</tbody>
</table>

**THURSDAY, Oct 5, 2007**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speakers</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>COS: Keratoconus and cornea grafting</td>
<td>G. Thuret, P. Kestelyn</td>
<td>Europe C</td>
</tr>
<tr>
<td>09:00</td>
<td>POSTER session 1: Anatomy/Cell Biology - Cornea/Corneal Surface (COS)</td>
<td>M. Hawlina, J. Guggenheim</td>
<td>Europe C</td>
</tr>
<tr>
<td>10:15</td>
<td>Keynote Lecture 2: Antigen-presenting cells and the eye</td>
<td>Martine JAGGER</td>
<td>Europe A</td>
</tr>
<tr>
<td>12:30</td>
<td>THEA Luncheon: COS - New evaluation techniques in corneal surface disease</td>
<td></td>
<td>Europe A</td>
</tr>
<tr>
<td>14:00</td>
<td>Keynote Lecture 3: New perspectives in corneal imaging; fundus autoregulation and age-related macular degeneration</td>
<td></td>
<td>Europe A</td>
</tr>
<tr>
<td>19:00</td>
<td>COS / ACB - Poster session 2: Lens/Cataract (COS) - Pathology/Oncology - Retina/Vitreous</td>
<td>R. Asoklu, H. Dua</td>
<td>Europe C</td>
</tr>
</tbody>
</table>

**FRIDAY, Oct 6, 2007**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speakers</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>COS: Corneal transplantation: layer by layer</td>
<td>P. Kestelyn, G. Lachnich</td>
<td>Europe A</td>
</tr>
<tr>
<td>10:15</td>
<td>Ophthalmic Research Lecture: Active subretinal implants in seven blind patients: outcome of a pilot study and further developments</td>
<td>Eberhard Zrenner</td>
<td>Europe A</td>
</tr>
<tr>
<td>12:30</td>
<td>LUNCHTIME</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td>POSTER session 3: Neuro-ophthalmology - Strabismus/Paediatric Ophthalmology - History</td>
<td>K. Kauffman, H. Lohst</td>
<td>Europe C</td>
</tr>
<tr>
<td>16:00</td>
<td>POSTER session 4: Intraocular Pressure in corneal disease</td>
<td>T. Zeev, M. Pachon</td>
<td>Europe C</td>
</tr>
</tbody>
</table>

**SUNDAY, Oct 7, 2007**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speakers</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td>COS: Assessment of the cornea</td>
<td>J. Mastropasqua, H. Dua</td>
<td>Europe A</td>
</tr>
<tr>
<td>10:15</td>
<td>Keynote Lecture 4: Novel forms of treatment for dry eye disease</td>
<td>J. Wood, J. Guggenheim</td>
<td>Europe A</td>
</tr>
<tr>
<td>12:30</td>
<td>LUNCHTIME</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td>Keynote Lecture 5: New developments in corneal disease</td>
<td>J. Zrenner, G. Lohst</td>
<td>Europe C</td>
</tr>
<tr>
<td>16:00</td>
<td>Keynote Lecture 6: Innovative approaches in corneal disease</td>
<td>G. Thuret, P. Kestelyn</td>
<td>Europe C</td>
</tr>
<tr>
<td>19:00</td>
<td>Session 7: EBO exam Course - Bahram BODAGHI - Room Daphnia</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>